

## AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (March 2003), Supplement 2 (April 2003), Supplement 3 (April 2003), Supplement 4 (April 2003), and Supplement 5 (June 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

- |                         |                           |                            |
|-------------------------|---------------------------|----------------------------|
| Aaron, L., E13          | Bazzi, C., 328            | Campese, V.M., 565         |
| Abbott, K.C., 796, 1267 | Beaufils, H., 1205        | Campolo, G., 1278          |
| Abraham, W.T., 571      | Becker, B.N., S4:27       | Canas, G., xl              |
| Agarwal, R., 651, 752   | Bedinger, M.R., 433       | Caplin, N., 429            |
| Agodoa, L.Y., 796, 1267 | Behets, G.J., 997         | Caridi, G., 95, 1314       |
| Ahmad, S., S4:44        | Bender, W.L., 386         | Carnethon, M.R., 580       |
| Ahuja, T.S., 279, 1060  | Berman, S., 196           | Carpenter, B., 212         |
| Akagi, S., 624          | Bernardini, J., 664       | Carroll, R.P., 676         |
| Akbari, A., E17         | Bertelli, R., 1314        | Case, C., 1016             |
| Akkaya, V., 616         | Berthou, F., 558          | Chadban, S.J., 596         |
| Al Ajami, A., 709       | Bervoets, A.R.J., 997     | Chae, D.-W., 1037          |
| Al Arrayed, A., 709     | Bhandari, S., E1          | Chaignon, M., E20          |
| Albaqali, A., 709       | Bhathena, D.B., 1179      | Chan, C., 225, 403         |
| Albright, R.C., 702     | Bianchi, S., 565          | Chan, K.W., E21            |
| Al Mahroos, H., 709     | Bigazzi, R., 565          | Chan, M. H.-M., 250        |
| Almond, M.K., 776       | Bingham, J., 1322         | Chang, I.J., 508           |
| Alongi, G., 1278        | Bisegna, S., 1278         | Chang, Y.S., 422           |
| Altimari, A., 1303      | Bleeker-Rovers, C.P., E22 | Chao, T.-Y., 1052          |
| Álvarez-Ude, F., E9     | Bletry, O., 1205          | Chauveau, D., 550, 1205    |
| Ando, T., 972           | Bleyer, A.J., 990         | Cheek, D.E., 1097          |
| Ansari, A., 523         | Bliwise, D.L., 394        | Cheong, H.I., 238          |
| Araki, I., 637          | Bobelu, A., 1195          | Cherr, G.S., 990           |
| Aronoff, G.R., 433      | Bochenski, J., 1189       | Cheunsuchon, B., 508, 1116 |
| Arrigo, G., 328         | Bocquet, N., 550          | Chieco, P., 1303           |
| Arroyo, A., E9          | Boelaert, J.R., 877       | Chiurchiu, C., E4          |
| Asakimori, Y., 822      | Boeschoten, E.W., 1293    | Chkhutua, A.B., 1303       |
| Asif, A., E18           | Boletis, J.N., 29         | Chng, W.J., 692            |
| Asim, M., 696           | Bondia, A., 488           | Cho, B.S., E6              |
| Assadi, F., E3          | Boomsma, F., 807          | Choi, B.S., E6             |
| Astor, B.C., 1          | Booth, A.D., 776          | Choi, K.H., 943            |
| Atkins, R.C., 132, 596  | Borgmann, S., 933         | Choi, S.J., E11            |
| Aubert, P., E20         | Bostom, A.G., 442         | Choi, Y., 238              |
| Averbukh, Z., 196       | Boudville, N., 658        | Choi, Y.H., E11            |
| Avni, Y., E2            | Bourgoignie, J.J., E18    | Choi, Y.J., 422, E6        |
| Avorn, J., 84           | Brackbill, E.L., E3       | Chong-Lopez, A., 696       |
| Bacchetti, P., 162, 447 | Braden, G.L., 1247        | Chow, F.Y.F., 596          |
| Bagiatoudi, G., E15     | Bragg-Gresham, J.L., 605  | Chow, K.-M., 250           |
| Bailey, J.L., 394       | Bridoux, F., 497          | Chu, P., 1052              |
| Bairaktari, E.T., 1225  | Brier, M.E., 433          | Chuahirun, T., 13          |
| Bajema, I.M., 532       | Briganti, E.M., 596       | Chung, W.K., 891           |
| Baker, R.J., 670        | Brophy, P.D., 984         | Clemenger, M., 670         |
| Bakker, S.J.L., 859     | Brown, E.A., 670          | Clopton, P., 571           |
| Bakris, G.L., 1267      | Broyer, M., 550           | Coche, E., E8              |
| Balduini, C.L., 95      | Bruijn, J.A., 532         | Cogné, M., 497             |
| Banerjee, D., E18       | Bunchman, T.E., 984       | Cohen, N., 196             |
| Bang, B.K., 422, E6     | Burke, G.L., 990          | Cohn, M., 196              |
| Bárány, P., 12122       | Burns, A., 776            | Collinge, N., 1060         |
| Barenbrock, M., 1088    | Butani, L., 760           | Comper, W.D., 336          |
| Bartlett, S.T., 849     | Buzza, M., 1170           | Concato, J., 105           |
| Basile, G., 1314        |                           | Connaire, J., xli          |
| Bastacky, S., E7        | Caiazza, A., 565          | Consugar, M., 90           |
|                         | Cain, J.A., 433           |                            |

- Corbacho, L., 488  
 Coresh, J., 1, 149  
 Corey, H., 259  
 Corstens, F.H.M., E22  
 Cosnard, G., E8  
 Coyne, D.W., 651  
 Craven, T.E., 990  
 Cruess, D., 796  
 Curhan, G., 1240  
 Curhan, G.C., 588, 643  
 Curtin, R.B., 1286  
  
 D'Agati, V.D., 259, 714, 891, 1327  
 Daghar, H., 1170  
 Dagnino, M., 1314  
 Dahl, N., 651  
 Dahlstrom, L.R., 76  
 D'Amico, G., 328  
 Dams, G., 997  
 Daphnis, E., 29  
 Davis, C.L., 76  
 Davison, D.L., E14  
 Dean, R.H., 990  
 Deaton, D., 1247  
 De Broe, M.E., 997  
 De Chazal, I., 702  
 Decourt, C., 497  
 de Jong, P.E., 733, 859  
 de Jongh, S., 684  
 Dekker, F.W., 1293  
 Delahousse, M., E20  
 Dembinska-Kieć, A., 203  
 De Pauw, R., 877  
 Deray, G., 292  
 D'Errico, A., 1303  
 de Sévaux, R.G.L., E22  
 de Tovar, G., E20  
 de Vries, A.P.J., 859  
 DeVriese, A.S., 877  
 de Zeeuw, D., 733  
 D'Haese, P.C., 997  
 Dhiman, R.K., 709  
 Diaz-Mitoma, F., 212  
 Di Duca, M., 1314  
 DiMauro, S., 259  
 Dixit, M.P., E16  
 Dooley, M.A., 455  
 Doss, S., 1008  
 Doyle, J., 171  
 Duc, P., 571  
 Dudley, R.A., 171  
 Dumoulin, A., 38  
  
 Edwards, M.S., 990  
 Efrati, S., 196  
 Eggers, P.W., 433  
 Eknoyan, G., 1, 868, S4:1, S5:3  
 Elisaf, M.S., 1225  
 El-Jazzar, K.M., E14  
 El Kossi, M.M.H., 785  
 Ellis, P., 776  
  
 El Nahas, A.M., 785  
 Emma, F., 1314  
 Emmett, M., 230  
 Endisch, G., 933  
 Endoh, M., 950  
 Engelman, R., 1247  
 Ertürk, S., 1233  
 Eustace, J.A., 351  
 Evans, A., S4:4  
 Evans, S., 493  
  
 Fabrizi, F., 1278  
 Fakhouri, F., 550, E13, 1205  
 Falk, A., 429  
 Falkenhain, M.E., 962  
 Faratro, R., 225  
 Farias, K.B., E16  
 Fathi, R., 1016  
 Feber, J., 212  
 Federick, P.R., 433  
 Fehrman-Ekholm, I., 1212  
 Ferluga, D., 539  
 Fernández-Reyes, M.J., E9  
 Ferrario, F., 532  
 Ferraz, M.B., 186  
 Ferris, M.E., 455  
 Filler, G., 212  
 Fink, N.E., 149  
 Firrincieli, A., E4  
 Fish, D.N., 269  
 Fishbane, S., S5:1, 18  
 Flack, J., 1247  
 Flanigan, M.J., 840  
 Flaute, R.P., 125  
 Fogo, A.B., xxxii, 508, xlvii, i  
 Folkert, V.W., 651  
 Fordtran, J.S., 230  
 Forget, C., 212  
 Fortmann, S.P., 580  
 Frankenfield, D.L., 433, 840  
 Frederick, P., 840  
 Fricke, H., 933  
 Fridolin, I., 1026  
 Fried, L., 664  
 Friedman, A.N., 442, 480  
 Fritz, B.A., 1008  
 Fryer, A.A., 676  
 Fujigaki, Y., E10  
 Fujimi, S., 972  
 Fukasawa, M., 637  
 Fukuda, K., 371  
 Fulladosa, X., 1065  
 Fusaroli, M., E4  
  
 Gabor, J.Y., 403  
 Gabusi, E., 1303  
 Gagnadoux, M.-F., 550  
 Galperin, E., 196  
 Gangarossa, S., 95  
 Gans, R.O.B., 733, 859  
 Garcia, P., 488  
  
 Garrido, J., 488  
 Garvin, J., 891  
 Gaskin, G., 776  
 Geiger, X., 1116  
 Genchallac, H., 616  
 Germain, M., 1247  
 Gesto, R., E9  
 Ghiggeri, G.M., 95, 1314  
 Ghuloom, A., 709  
 Giatromanolaki, A., 360  
 Ginevri, F., 1314  
 Gipson, D.S., 455  
 Godbole, M., 1163  
 Goldfarb, D.S., 220  
 Goldsmith, D., 493, 523  
 Goldsmith, D.J.A., 1322  
 Goldstein, M., E12  
 Goldstein, S.L., 984  
 Golper, T.A., S4:27  
 Goodkin, D.A., 605  
 Goral, S., S4:27  
 Gordon, I., 493  
 Grady, J., 1060  
 Greene, T., 1, 962  
 Gregory, M.J., 984  
 Grigioni, W.F., 1303  
 Grinyó, J.M., 1065  
 Grünfeld, J.-P., 550, E13, 1205  
 Guery, B., E13  
 Guirl, M.J., 230  
 Gulati, K., 1163  
 Gulati, S., 1163  
 Gupta, M., 212  
  
 Ha, I.S., 238  
 Ha, S.-K., 943  
 Hacker, U.T., 933  
 Haenebalcke, C.W., 877  
 Hagen, C., 532  
 Hahn, H., 238  
 Hall, A.V., 1140  
 Haluska, B., 1016  
 Han, D.S., 943  
 Hanly, P.J., 403  
 Hansen, K.J., 990  
 Harden, P.N., 676  
 Hariachar, S., 742  
 Harris, P.C., 90  
 Hartikainen, J., 1219  
 Haruki, S., 1155  
 Hata, J.-i., 1110  
 Hataya, H., 1110  
 Hatzidimou, K.G., 1225  
 Hauer, H.A., 532  
 Haugen, E.N., 702  
 Hausberg, M., 1088  
 Hawley, C.M., 676  
 Hayashi, S., 1155  
 Haymann, J.-P., E20  
 Hebbat, S., 386  
 Hebert, L.A., 962

- Hébert, M.-J., 1043  
 Heimbürger, O., 1212  
 Held, P.J., 605  
 Helin, H., 343  
 Henning, P., 1170  
 Heras, M., 488  
 Hernández, E., 319  
 Herrmann, H.C., 571  
 Hida, K., 624  
 Hill, G.S., 38  
 Hirakata, H., 371  
 Hirakawa, M., 371  
 Hirano, T., 371  
 Hiraoka, M., 1155  
 Hishida, A., E10  
 Hofmann, A.F., 230  
 Hogan, S.L., 455  
 Hollander, J.E., 571  
 Honda, M., 1110  
 Hong, S.Y., E11  
 Hons, R., 380  
 Hoppel, C., S4:4  
 Hörl, W.H., 49  
 Hotta, O., 244  
 Hsu, C.-y., 162  
 Huang, K., 455  
 Hueso, M., 1065  
 Hurray, C., 1097  
 Hussain, N., E17  
 Hwang, H.J., 943  
  
 Ichikawa, H., 624  
 Ieiri, N., 244  
 Iglesias, J., 62  
 Iida, M., 371  
 Iijima, K., 366  
 Ikäheimo, R., 1219  
 Ikeda, K., 972  
 Ikeda, M., 1110  
 Ikizler, T.A., 616  
 Imam, K., 351  
 Inada, T., 833  
 Ioannidis, J.P.A., 29  
 Isbel, N., 1016, 1170  
 Ishihara, K.K., E5  
 Isnard-Bagnis, C., 292  
 Isozaki, T., E10  
 Ito, S.-i., 1110  
 Izzedine, H., 292  
  
 Jamsheer, A., 709  
 Janckila, A.J., 1052  
 Janda, K., 203  
 Janssen, W. M.T., 733  
 Janusz-Grzybowski, E., 203  
 Jayne, D.R.W., 776  
 Jelacic, S., 709  
 Jerums, G., 336  
 Jevnikar, A.M., 1140  
 Jinde, K., 950  
 Johansen, K.L., 162, 171, 447  
  
 Johnson, D.W., 1016  
 Johnson, J.P., E7  
 Johnston, T.D., 464  
 Juncos, L.A., 702  
 Jung, J.Y., E6  
  
 Kainer, G., 1170  
 Kakafika, A.I., 1225  
 Kaklamanis, L., E15  
 Kamiyama, M., 637  
 Kanai, H., 371  
 Kanakiriya, S., 702  
 Kang, B.S., 943  
 Kang, H.G., 238  
 Kang, S.W., 943  
 Kapitsinou, P.P., 29  
 Kaplan, B.S., 709  
 Kaplan, K.L., 471  
 Kaplan-Pavlovic, S., 539  
 Kasuno, K., 767  
 Katafuchi, R., 972  
 Kaufman, P., 259  
 Kausz, A.T., 76  
 Kawamura, S., 1110  
 Kazanegra, R., 571  
 Kelly, K.J., 1074  
 Kerr, P.G., 132, 596  
 Keven, K., 1233  
 Khan, S., 1060  
 Khanna, A., 13  
 Khoo, M.S.C., 1247  
 Kikuchi, H., 1110  
 Kim, D.H., 943  
 Kim, G.-H., 1037  
 Kim, G.A., 1257  
 Kim, H.-J., 1037  
 Kim, H.S., E6  
 Kim, H.W., E6  
 Kim, J., E6  
 Kim, M.-J., 1257  
 Kim, N., E11  
 Kim, N.I., 422  
 Kim, S.-G., 1037  
 Kim, S.J., 943, E12  
 Kim, W.Y., 422  
 Kim, Y.O., 422  
 Kim, Y.S., E6  
 Kimball, K., 13  
 Kirwin, P., 105  
 Klag, M.J., 149  
 Klahr, S., 962  
 Klimeczek, P., 203  
 Knebelmann, B., 550, E13  
 Knight, E.L., 588  
 Knudsen, C.W., 571  
 Kohno, N., 822  
 Koo, J.-R., 1037  
 Koomans, H.A., 684  
 Korevaar, J.C., 1293  
 Kosch, M., 1088  
 Koscica, J., 714  
  
 Koselj-Kajtina, M., 539  
 Kovesi, T., 212  
 Kozak, K.R., E5  
 Kramer, H.K., 1233  
 Kramer, H.M., 588, 643  
 Krediet, R.T., 1293  
 Krepel, H.P., 807  
 Krisnaswamy, P., 571  
 Krolewski, A.S., 22, 1189  
 Kronenberg, F., 140  
 Kubo, M., 371, 972  
 Kuboki, T., 833  
 Kumano, H., 833  
 Kung, W.H., E21  
 Kusano, H., 767  
 Kutlay, S., 1233  
 Kwakye, J., 1327  
 Kwon, O., 1074  
  
 Laakso, M., 1219  
 Labrador, P.J., 488  
 Lacson, E. Jr., 111  
 Laliberty, P., 442  
 Lamba, S., 571  
 Lampainen, E., 1219  
 Landais, P., 550  
 Längle, M., 140  
 Langman, C.B., S4:27  
 Larson, T.S., 760  
 Latos, D.L., 868  
 Launay-Vacher, V., 292  
 Lazarus, J.M., 111  
 Lebon, P., 1205  
 Lee, E.-Y., E11  
 Lee, E.J., 422  
 Lee, H.S., E11  
 Lee, H.Y., 943  
 Lee, S.-K., 1037  
 Lee, S.W., 1257  
 Lee, T.H., 943  
 Lee, Y.-K., 1037  
 Leon, J.B., 125  
 León, M., 319  
 LePain, N., 1286  
 Lerma, J.L., 488  
 Lesavre, P., 550, 1205  
 Levey, A., 962  
 Levey, A.S., 1, 149, 480  
 Levin, R., 84  
 Levine, J.S., 62  
 Levinsky, N.G., 723  
 Li, P. K.-T., 250  
 Li, R., E21  
 Liangos, O., 742  
 Lilien, M.R., 684  
 Lim, H.J., 1257  
 Limcangco, M.R., 849  
 Limido, A., 1278  
 Lin, Y.-F., 1052  
 Lindberg, J., 868  
 Lindberg, J.S., S4:1

- Lindberg, L.-G., 1026  
 Lindholm, B., 1212  
 Linossier, M.-T., 558  
 Liu, T.C., 692  
 Long, E.D., E1  
 Lopes, A.A., 605  
 Lowrie, E.G., 1286  
 Lucas, B.A., 464  
 Lucas, M.F., 814  
 Lumiaho, A., 1219  
 Lunghi, G., 1278  
  
 MacCluer, J.W., 1195  
 Macdougall, I.C., 49  
 MacKinnon, M., E17  
 MacLean, D., 493  
 Mac-Moune Lai, F., 250  
 Madore, F., 1043  
 Magnusson, M., 1026  
 Magrini, U., 95  
 Mahnensmith, R., 105  
 Maisel, A.S., 571  
 Makino, H., 624  
 Makita, Y., 1189  
 Mangano, S., 1278  
 Manley, H.J., 386  
 Manno, C., 1129  
 Manns, B., 380  
 Mapes, D.L., 605  
 Marboe, C., 891  
 Marcén, R., 814  
 Mardirossian, S., 225  
 Marik, P.E., 62  
 Markowitz, G.S., 259, 714, 891  
 Martin, A.A., 149  
 Martinez, F., 1205  
 Marwick, T.H., 1016  
 Masse, M., 1043  
 Massella, L., 1314  
 Masuda, M., 366  
 Masutani, K., 371, 972  
 Matsubara, K., 1155  
 Matsumori, A., 767  
 Matsushita, K., 637  
 Matsuyama, N., 833  
 Matthys, E.G., 877  
 Mayumi, M., 1155  
 Mbonu, C.C., E14  
 McAfee, N., 984  
 McCann, L.M., 1008  
 McClaran, M.L., 386  
 McClellan, W.M., 903  
 McCord, J., 571  
 McCullough, K., 605  
 McCullough, P.A., 571  
 McGowan, T., 903  
 McKeown, J.W., 464  
 McLaughlin, K., 380  
 McQuade, M., E16  
 Melikian, N., 1322  
 Mercanoglu, F., 616  
  
 Mesnard, L., E20  
 Meyer, K.B., 149  
 Meyrier, A., 38  
 Michael, B., 651  
 Michael, R., 493  
 Miettinen, R., 1219  
 Mikami, Y., 637  
 Milam, R.A., 433  
 Milford, E.L., 411  
 Miller, B., S4:44  
 Miller, F.J., 508  
 Miskulin, D.C., 149, 480  
 Miyake, K., 371  
 Mizumasa, T., 972  
 Moczulski, D.K., 1189  
 Modai, D., 196  
 Molitoris, B.A., 1074  
 Mon, C., E9  
 Montseny, J.-J., 38  
 Moody, H., 658  
 Morales, E., 319  
 Moresco, F., 1065  
 Morgenstern, B.Z., 760  
 Morikawa, Y., 1110  
 Mormoi, T., 1155  
 Mortis, G., 380  
 Moss, A.H., 723  
 Moutsopoulos, H.M., 29  
 Mulhearn, J., 1247  
 Mullins, C.D., 849  
 Mündle, M., 140  
 Murer, L., 1314  
 Muso, E., 767  
 Mustonen, J., 343  
 Muther, R.S., 386  
 Myers, D.I., 351  
 Myrski, P., 651  
 Myllymäki, J., 343  
  
 Nadasdy, T.A., 471  
 Nagake, Y., 624  
 Nahashima, H., 371  
 Nakanishi, K., 366  
 Nakao, K., 624  
 Nakopoulou, L., 29  
 Nandagopal, R., 76  
 Nangaku, M., 833  
 Napodano, P., 328  
 Narva, A.S., 1195  
 Nasr, S.H., 259  
 Nasr, S.H., 714, 891  
 Nath, K.A., 702  
 Navis, G., 733  
 Necchi, V., 95  
 Neild, G.H., 776  
 Neimark, S., 230  
 Nelson, D., 742  
 Nergizoglu, G., 1233  
 Neri, T.M., 1314  
 Nette, R.W., 807  
 Neufeld, T.K., 386  
  
 Neyer, U., 140  
 Ng, D.P.K., 22  
 Nguyen, S.T., 220  
 Niauxet, P., 550  
 Nickeleit, V., 696  
 Nicol, D.L., 676  
 Niemitukia, L., 1219  
 Nishi, T., 833  
 Noël, L.-H., 532, 1205  
 Nogaki, F., 767  
 Noh, J.-W., 1037  
 Noris, P., 95  
 Nowak, R.M., 571  
  
 O'Brien, W.A., 279  
 Ofiaz, H., 616  
 Ofsthun, N., 111  
 Oh, K.-H., 1037  
 O'Hare, A.M., 162, 447  
 Ohashi, N., E10  
 Ohi, H., 179  
 Ohshima, Y., 1155  
 Ohta, K., 1155  
 Okada, N., 179  
 Okamoto, A., 624  
 Omland, T., 571  
 Ono, T., 767  
 Op't Roodt, J., 684  
 Orte, L., 814  
 Ortuño, J., 814  
 O'Shea, M., 1247  
 Osicka, T.M., 336  
 Ota, K., 624  
 Otsuka, T., 371  
 Overbay, D.K., 386  
 Owen, S., 1247  
 Oyén, W.J.G., E22  
  
 Paganini, E.P., 742  
 Pagliari, B., 1278  
 Paine, S., 1195  
 Palaniappan, L., 580  
 Palle, S., 558  
 Pancrudo, J., 259  
 Paparella, M., 328  
 Papo, T., 1205  
 Park, H.S., 943  
 Park, J.C., 943  
 Parker, K.P., 394  
 Pasadakis, P., 360  
 Pasowicz, M., 203  
 Pasternack, A., 343  
 Pastural, M., E20  
 Paulson, W.D., 518  
 Pauly, D.F., S4:35  
 Pecci, A., 95  
 Pecoits-Filho, R., 1212  
 Peel, R., E1  
 Pepine, C.J., S4:35  
 Perez, A., 571  
 Perfumo, F., 1314

- Persu, A., E8  
 Pesavento, T.E., E19  
 Pescovitz, M., 1074  
 Petrini, C., 328  
 Piedmonte, M.R., 742  
 Pierratos, A., 403, E12  
 Piette, J.-C., 1205  
 Pifer, T., 605  
 Pihlajamäki, J., 1219  
 Pinto-Sietsman, S.-J., 733  
 Piraino, B., 664  
 Pirson, Y., E8  
 Pisano, L., 328  
 Plaisance, M., 776  
 Poldermans, D., 807  
 Polenakovic, M.H., 997  
 Polhinghorne, K.R., 132  
 Ponticelli, C., 1278  
 Poole, L.J., 351  
 Port, F.K., 605  
 Porter, J.L., 230  
 Powe, N.R., 149, 505  
 Pradel, F.G., 849  
 Praga, M., 319  
 Presne, C., 550  
 Preston, R.A., E18  
 Pritsivelis, N., 1225  
 Prowant, B., 840  
 Pusey, C.D., 776  
 Pusuroglu, H., 616  
  
 Quereda, C., 814  
 Quoidbach, A., E8  
  
 Rabenou, R.A., 220  
 Rahn, K.-H., 1088  
 Ramalakshmi, S., E7  
 Ramsay, H.M., 676  
 Rana, K., 1170  
 Rangan, A., 658  
 Ranjan, D., 464  
 Ravazzolo, R., 95  
 Raynaud, A., E20  
 Reddy, K.S., 464  
 Reid, G.M., 386  
 Reisman, J., 212  
 Remuzzi, G., E4  
 Renwick, N., 891  
 Reynolds, J.C., 796  
 Richardson, R.M.A., 225  
 Rizza, V., 328  
 Rizzoni, G., 1314  
 Rocco, M.V., 840  
 Rodrigues-Neto, J., 186  
 Rollino, C., xlvii  
 Romagnoli, R., 95  
 Ron, Y., E2  
 Rosenber, I.H., 480  
 Rosenberg, R., 196  
 Rossert, J., 49  
 Rossetti, S., 90  
  
 Roth, D., E18  
 Rott, T., 539  
 Rousou, J., 1247  
 Rozman, B., 539  
 Rubel, J.R., 411  
 Ruggenti, P., E4  
 Rutkowski, B., 49  
 Rye, D.B., 394  
  
 Saha, H., 343  
 Sakai, H., 950  
 Sakhas, G.K., 171  
 Salahudeen, A.K., 925  
 Salpigidis, K., E15  
 Sánchez, R., E9  
 Sandrini, S., 1314  
 Sanna-Cherchi, S., 1314  
 Santa, C.A., 230  
 Santostefano, M., E4  
 Sarnak, M.J., S5:11  
 Sarris, E., E15  
 Sartore, S., 95  
 Satayathum, S., 605  
 Savige, J., 1170  
 Savoia, A., 95  
 Scavini, M., 1195  
 Schaefer, R.M., 1088  
 Schatell, D., 1286  
 Scheel, P.J., 351  
 Schena, F.P., 1129  
 Schoolwerth, A.C., 903  
 Schröder, C.H., 684  
 Schurgers, M.S., 877  
 Schwimmer, J., 471  
 Scolari, F., 1314  
 Scott, K.M., E16  
 Sedlacek, M., 429  
 Segal, M., 162  
 Sehgal, A.R., 125  
 Self, S.E., 1097  
 Selhub, J., 442  
 Sellars, L., E1  
 Senior, H., 670  
 Seo, Y.S., E11  
 Serferiadis, K.I., 1225  
 Seri, M., 95  
 Serón, D., 1065  
 Sessa, A., 95  
 Sesso, R., 186  
 Sever, M.S., 616  
 Shaer, A.J., 1097  
 Shah, S., E5  
 Shah, V.O., 1195  
 Shanske, S., 259  
 Shaw, L., 212  
 Shemin, D., 442  
 Sherman, D.S., 269  
 Shimoyama, H., 833  
 Shome, D.K., 709  
 Shubert, T., 171  
 Shulman, G., E5  
  
 Siakotos, M., E15  
 Simon, G.L., E14  
 Singh, A., 643, 1240  
 Singh, U., 1163  
 Sirois, I., 1043  
 Sivridis, E., 360  
 Slezak, J., 90  
 Smetana, S., E2  
 Smiles, A.M., 1189  
 Somers, M.J.G., 984  
 Son, B.-K., 1037  
 Song, B.-S., 933  
 Song, H.C., 422  
 Song, J.H., 1257  
 Soo, Y.O.-Y., 250  
 Sorin, V., E2  
 Sotsiou, F., 29  
 Spasovski, G.B., 997  
 Spitalnik, P.F., 471  
 Srivastava, A., 1163  
 St. Peter, W.L., 903  
 Stablein, D., 464  
 Stack, A.G., 310  
 Staffeld-Coit, C., 1116  
 Stavrianaki, D., E15  
 Stefoni, S., 1303  
 Steg, P.G., 571  
 Stenvinkel, P., 1212  
 Stewart, L.R., 1097  
 Stidley, C.A., 1195  
 Stokes, M.B., 220, 1327  
 Stompór, T., 203  
 Storow, A.B., 571  
 Stratta, R.J., 464  
 Striker, L., E18  
 Strippoli, G.F.M., 1129  
 Strees, E.S., 684  
 Sudo, S., 179  
 Suganuma, N., 1155  
 Sugiura, T., E10  
 Suliman, M., 1212  
 Sulowicz, W., 203  
 Suwelack, B., 1088  
 Symons, J.M., 984  
 Szabo, T., E12  
 Szeto, C.-C., 250  
  
 Tabernero, J.M., 488  
 Tagumna, Y., 244  
 Takai, J., 833  
 Takata, A., 1110  
 Takeda, M., 637  
 Takeda, N., 1155  
 Tam, V.K.K., E21  
 Tamano, M., 179  
 Tan, L.K., 692  
 Tanaka, H., 972  
 Tanaka, J., 822  
 Taranto, S., 464  
 Tarr, P.I., 709  
 Taub, K., 380

- Taupin, P., 550  
 Tawney, K., 447  
 Taylor, A.J., 1267  
 Taylor, J., 493  
 Teitelbaum, I., 269  
 Tentori, F., 1195  
 Teodorescu, V., 429  
 Termorshuizen, F., 1293  
 Terrado, L.T., E19  
 Teruel, J.L., 814  
 Tettamanzi, F., 1278  
 Thakar, C.V., 742  
 Thaker, H.M., 891  
 The, T.H., 859  
 Therby, A., E13  
 Thi, T.X.N., 220  
 Thomas, S., 523  
 Togawa, A., E10  
 Torras, J., 1065  
 Torres, V.E., 90  
 Touam, M., E13  
 Touchard, G., 497  
 Touloupidis, S., 360  
 Tracz, W., 203  
 Trespalacios, F.C., 796, 1267  
 Troyanov, S., 1043  
 Tsele, E., E15  
 Tsianos, E.V., 1225  
 Tsukahara, H., 1155  
 Tsurusawa, M., 1155  
 Tsuruya, K., 371  
 Tuttle, K.R., 76  
  
 Uhlin, F., 1026  
 Uribarri, J., 429  
  
 Valderrábano, F., 49  
 Valero, M.A., 319  
  
 van den Dorpel, M.A., 807  
 van den Meiracker, A.H., 807  
 van der Heide, J.J.H., 859  
 van der Woude, F.J., 532  
 van Gurp, E., 532  
 van Hamersvelt, H.W., E22  
 Van Hoof, V.O., 997  
 van Houwelingen, H.C., 532  
 van Manen, J.G., 1293  
 van Son, W.J., 859  
 Vargemzis, V., 360  
 Vergunst, C.E., 532  
 Vienken, J., 1303  
 Vigneault, N., 1043  
 Vizjak, A., 539  
  
 Wada, J., 624  
 Waid, T.H., 464  
 Wai-Kei Lam, C., 250  
 Waldherr, R., 532  
 Walker, D., 90  
 Wang, Q., 664  
 Warnock, D.G., 651  
 Warram, J.H., 22, 1189  
 Watanabe, H., 767  
 Watnick, S., 105  
 Wauters, J.P., 49  
 Weber, M.L., xli  
 Weimar, W., 807  
 Weissgarten, J., 196  
 Wells, H., 493  
 Welty, T.K., 1195  
 Wesson, D.E., 13  
 Westheim, A., 571  
 Wilmer, W.A., E19  
 Wilson, D.M., 760  
 Winearls, C.G., 90  
 Winkelmayer, W.C., 84  
  
 Wish, J.B., 254  
 Wójcik, K., 203  
 Wolfe, R.A., 605  
 Wollan, P., 760  
 Worrall, N.K., 76  
 Wright, M.A., 386  
 Wrone, E.M., 580, 1008  
 Wu, A.H.B., 571  
 Wu, Q., 950  
  
 Xuan, B.H.N., 220  
  
 Yakubovich, M., 1303  
 Yam, L.T., 1052  
 Yamagata, Z., 637  
 Yamamoto, T., E10  
 Yanase, T., 972  
 Yang, C.W., 422, E6  
 Yang, J.O., E11  
 Yared, J.-P., 742  
 Yildiz, A., 616  
 Yodoi, J., 767  
 Yonemura, K., E10  
 Yoon, J.-W., 1037  
 Yoon, S.A., 422  
 Yorioka, N., 822  
 Yoshikawa, N., 366  
 Yoshizawa, N., 366  
 Young, E.W., 605  
 Yussim, A., 1303  
  
 Zafirovska, K., 997  
 Zager, P.G., 1195  
 Zaman, F., 518  
 Zand, M.S., 471  
 Zdzienicka, A., 203  
 Zietse, R., 807  
 Zimmet, P.Z., 596  
 Zuber, J., E13, 1205

## SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (March 2003), Supplement 2 (April 2003), Supplement 3 (April 2003), Supplement 4 (April 2003), and Supplement 5 (June 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

- Abdominal aortic aneurysm, causing obstructive acute renal failure, E9  
*N*-Acetylcysteine (NAC), homocysteine levels in hemodialysis and, 442–446  
 Acidosis, in drug-induced Fanconi syndrome, 292–309  
 ACR. *See* Albumin-creatinine ratio  
 Actin, urinary, ARF prediction after ischemic injury in allografts, 1074–1087  
 Acute interstitial nephritis (AIN)  
   drug-induced, in allograft dysfunction, 1116–1121  
   zopiclone-induced, E17  
 Acute renal failure (ARF)  
   after accidental perchloroethylene ingestion, E11  
   after fish gallbladder ingestion, 220–224  
   after open-heart surgery, 724–751  
   in antiphospholipid syndrome, 1205–1211



- with backache, E1
- caused by inflammatory abdominal aortic aneurysm, E9
- caused by renal parenchymal malacoplakia, E21
- infantile, CRRT for, 984-989
- with nephrotic syndrome in diabetes mellitus, 1327-1333
- post-renal transplant thrombotic microangiopathy and, 471-479
- prediction after ischemic injury in allografts, 1074-1087
- with radical nephrectomy-associated rhabdomyolysis, E5
- in septic shock, proinflammatory cytokines and, 62-75
- Acute tubular necrosis (ATN)
  - after fish gallbladder ingestion, 220-224
  - pamidronate-induced, E18
- Acyclic nucleoside phosphonates, Fanconi syndrome induction and, 292-309
- Adefovir, Fanconi syndrome induction and, 292-309
- Adenovirus infection, of renal allograft, 696-701
- Adequacy
  - hemodialysis
    - comparison of database URR and hematocrit values, 433-441
    - daily, S1:112-115
    - dual dialyzers in parallel and series comparisons, 1008-1015
  - peritoneal dialysis, prescription changes and, 840-848
- Adjuvant vitamin C, effect on EPO response in hemodialysis, 1233-1239
- Adolescent dyslipidemia, treatment of, S3:56-58
- ADPKD. *See* Autosomal dominant polycystic kidney disease
- Advanced glycation end product inhibitors
  - development of, S1:42-47
  - progression of nephropathy and, S1:68-71
- Advanced glycation end products (AGEs)
  - cardiovascular risk in CRF and, S1:52-56
  - dietary, effect on rat remnant kidney model, S1:48-51
  - formation during CAPD, S1:57-60
  - nephrotoxicity, new therapies for, S1:42-47
  - peritoneal dysfunction in CAPD and, S1:61-67
- Adynamic bone disease, diagnostic markers in predialysis ESRD patients, 997-1007
- Age
  - left ventricular dysfunction in ESRD and, 1016-1025
  - prevalence of peripheral arterial calcification in ESRD and, 140-148
- AGEs. *See* Advanced glycation end products
- AIN. *See* Acute interstitial nephritis
- Albumin, hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89-95
- Albumin-creatinine ratio (ACR)
  - diabetic nephropathy progression and, 13-21
  - protein intake in healthy adults and, 580-587
- Albuminuria. *See also* Microalbuminuria
  - immuno-unreactive, in diabetes mellitus, 336-342
  - kidney function in US population and, 1-12
  - in predicting diabetic nephropathy progression, 13-21
- Allograft
  - adenovirus infection, 696-701
  - chronic nephropathy
    - in aging kidney, cyclin-dependent kinase inhibitor genes and, 1303-1313
    - with repeated rejections and tubular renal acidosis, E6
- dysfunction
  - drug-induced AIN in, 1116-1121
  - insulin resistance and, 859-867
- ischemic injury, ARF prediction after, 1074-1087
- rejection
  - control, low-protein intake for, S1:146-152
  - endothelium growth phenotype and, 1140-1154
  - stable, structural and functional correlations in, 1065-1073
- Alopecia, in hemodialysis patient caused by tinzaparin, E15
- Alport-like syndrome
  - basement membrane changes in Frasier syndrome, 1110-1115
  - nonmuscle myosin IIA abnormality in, 95-104
- Amino acid score, low-protein diet for very late stage CRF, S1:31-34
- Aminoglycosides
  - Fanconi syndrome induction and, 292-309
  - for peritonitis, residual renal function unaltered by, 670-675
- Amputation risk factors, in hemodialysis, 162-170
- Anaphylactoid-type reactions, from iron therapy, S5:18-25
- ANCA-associated disorders
  - glomerulonephritis
    - histologic and immunohistologic study of, 539-549
    - index for renal outcome in, 532-538
- ANCA associated-disorders
  - renal vasculitis, 5-year retrospective study, 776-784
- Anemia
  - comparison of database URR and hematocrit values, 433-441
  - effect of hemoglobin variability on management, 111-124
  - endothelial dysfunction and LVH in chronic hemodialysis, 616-623
  - erythropoietin therapy, vitamin C and, 1233-1239
  - in ESRD with HIV infection, 279-291
  - high-dose sodium ferric gluconate complex for, 651-657
  - levocarnitine for, 868-876, S1:116-122, S4:27-34
  - predialysis survey on, 49-61
  - promotion of cardiovascular disease in CKD, S5:11-17
  - rHuEPO hyporesponsive patients
    - CD34+ cells in, 624-636
    - levocarnitine for, S4:27-34
  - rHuEPO therapy mechanisms, 179-185
- Angina, levocarnitine therapy for, S4:35-43
- Angiomyolipoma, pulmonary lymphangioleiomyomatosis and, 877-883
- Angioplasty, delayed after renal thrombosis, E20
- Angiotensin-converting enzyme gene polymorphisms, diabetic nephropathy progression, 943-949
- Angiotensin-converting enzyme inhibitors
  - diabetic nephropathy progression, albuminuria and, 13-21
  - under usage in chronic dialysis of heart failure patients, 1267-1277
- Angiotensin II, CKD progression and, S1:3-7
- Anticancer drugs, Fanconi syndrome induction and, 292-309

- Anticardiolipin antibodies, in antiphospholipid syndrome, 1205-1211
- Anticonvulsants, Fanconi syndrome induction and, 292-309
- Anti-DNA antibodies, in antiphospholipid syndrome, 1205-1211
- Antigen-presenting cells, in crescentic glomerulonephritis, 950-961
- Antiglomerular basement membrane nephritis, Crohn's disease and, 1097-1109
- Antineutrophil cytoplasmic antibody associated -associated disorders. *See* ANCA-associated disorders
- Antioxidants, carnitine supplementation in hemodialysis and, S1:116-122
- Antiphospholipid antibodies, renal diseases associated with, 1205-1211
- Antiphospholipid syndrome, renal diseases associated with, 1205-1211
- Antiretroviral therapy, in ESRD with HIV infection, 279-291
- Antistreptolysin O, in Henoch-Schönlein nephritis, 366-370
- Antiviral agents, Fanconi syndrome induction and, 292-309
- Anxiety, restless legs syndrome in uremic hemodialysis, 833-839
- Aortic valve replacement, predictors of ARF after, 76-83
- Apolipoprotein E  
gene polymorphism, carotid atherosclerosis and, 822-832  
in lipoprotein glomerulopathy, lipid-lowering therapy for, 244-249
- Apoptosis  
endothelial cell, allograft function and, 1140-1154  
soluble Fas as predictor of atherosclerosis in ESRD, 1043-1051
- Apoptosis inhibitors, allograft survival and, 1140-1154
- ARF. *See* Acute renal failure
- Arterial distensibility, fluvastatin effects on hypercholesterolemic renal transplant recipients, 1088-1096
- Arterial stiffness, in pediatric renal transplant recipients, 684-691
- Arteriovenous fistula  
blood flow and resistance during hemodialysis, 132-139  
thrombosis risk, MTHFR gene polymorphism and, 637-642  
vasculature in women and, 429-432
- Asian traditional medicine, ichthyotoxic acute renal failure from, 220-224
- Aspergillus* graft infection, after cadaveric renal transplant, 488-492
- AST-120  
effect on tryptophan metabolism in uremia, S1:38-41  
gene expression in uremic kidney and, S1:8-14  
with low-protein diet, effect on creatinine slope in CRF, S1:35-37
- Atherosclerosis  
apoE polymorphism and, 822-832  
with diabetic nephropathy, renal artery stenosis in, 351-359  
in ESRD  
intima-media thickness of carotid artery and, S1:76-79  
peritoneal dialysis, chronic inflammation and, 203-211  
prevalence of peripheral arterial calcifications, 140-148  
soluble Fas as predictor of, 1043-1051  
iron in, S1:80-83  
renal transplant, insulin resistance and, 859-867
- ATN. *See* Acute tubular necrosis
- Atorvastatin, effect on proteinuria and progression of kidney disease, 565-570
- Atovaquone, for PCP in non-HIV hemodialyzed patient, E13
- ATP6B1* gene mutations, distal renal tubular acidosis and deafness in child and, 238-243
- Australia  
health-related quality of life in ESRD, 596-604  
post-renal transplant prediction of nonmelanoma skin cancer, 676-683
- Autosomal dominant polycystic kidney disease (ADPKD)  
D298 *ENOS* polymorphism in, 90-94  
diagnosis of renal and hepatic cysts by 18-FDG-PET, E22  
multiple thoracic paraspinal meningeal cysts in, E8  
type 1, insulin resistance and left ventricular hypertrophy in, 1219-1224
- Autosomal recessive distal renal tubular acidosis, *ATP6B1* gene mutations in, 238-243
- Backache, with renal failure, E1
- Basement membrane, Alport syndrome-like changes in Frasier syndrome, 1110-1115
- Beck Depression Inventory, for new dialysis patients, 105-110
- Bence Jones V $\kappa$ l light chain, in myeloma tubulopathy, 497-504
- Best practice guidelines, for anemia management, 49-61
- Beta-blockers, under usage in chronic dialysis, 1267-1277
- Bifidobacterium*, indoxyl sulfate levels in hemodialysis and, S1:142-145
- Bile acid replacement therapy, for short bowel syndrome, 230-237
- Bile acid sequestrants, for lipid lowering in kidney transplant recipients, S3:52-53
- Biochemical markers, of renal osteodystrophy in predialysis ESRD patients, 997-1007
- Bisphosphonate nephrotoxicity, mechanisms of, E18
- Blood pressure  
arteriovenous fistula blood flow during hemodialysis, 132-139  
elevated. *See* Hypertension  
high-normal, microalbuminuria and, 588-595  
reduction, effect on albuminuria and diabetic nephropathy progression, 13-21
- BMI. *See* Body mass index
- BNP. *See* Brain natriuretic peptide
- Body fat mass  
central distribution relationship to renal function impairment, 733-741  
in hemodialysis patients, S1:137-141
- Body mass index (BMI)  
survival on dialysis and, 925-932  
at time of renal transplantation, 480-487
- Bone alkaline phosphatase, renal osteodystrophy in predialysis ESRD patients, 997-1007
- Bone histomorphometry, of uremic patients on maintenance HD, 1052-1059



- Bone mineral density (BMD)  
in children with idiopathic nephrotic syndrome, 1163-1169  
in postmenopausal hemodialysis-dependent women, 1240-1246
- Boui-Ougi-Tou, Fanconi syndrome and, 292-309
- Brain natriuretic peptide (BNP)  
assessment of hydration status in hemodialysis, 1257-1266  
and renal function in heart disease diagnosis, 571-579
- Breathing Not Properly Multinational Study, BNP and renal function in heart failure diagnosis, 571-579
- Bronchoalveolar lavage, EBV load determination in children, 212-219
- Calcimimetics  
for secondary hyperparathyroidism, S1:100-103  
with vitamin D analogues, for secondary hyperparathyroidism, S1:104-107
- Calcineurin-inhibitor-based immunosuppression, thrombotic microangiopathy after, 471-479
- Calcinosis, daily home hemodialysis for, E12
- Calcitriol analogue, for secondary hyperparathyroidism, S1:100-103
- Calcium  
in cardiac valvular disease in hemodialysis patients, 411-421  
cystosolic, in hepatocytes in CRF, S1:127-132  
in diagnosis of renal osteodystrophy in predialysis ESRD patients, 997-1007  
metabolic alterations, promotion of cardiovascular disease in CKD, S5:11-17  
in secondary hyperparathyroidism, calcimimetics in, S1:104-107
- Calcium phosphate control, nocturnal hemodialysis for peripheral arterial disease, 225-229
- Caloric intake, oral nutritional supplementation for PD, 658-663
- CAPD. *See* Continuous ambulatory peritoneal dialysis
- Carbohydrate metabolism, in liver of chronic renal failure patient, S1:127-132
- Carbon absorbent, oral. *See* Oral absorbent
- Carboplatin, Fanconi syndrome induction and, 292-309
- N*ε-(Carboxymethyl)lysine (CML)  
accumulation in glomerular lesions, AGE inhibitor and, S1:68-71  
cardiovascular risk and, S1:52-56  
formation during CAPD, S1:57-60
- Cardiac calcification in hemodialysis, calcium-phosphate imbalance and, 411-421
- Cardiac surgery  
predictors of ARF after, 76-83  
for valvular disease, calcium-phosphate imbalance and, 411-421
- Cardiomyopathy  
congestive, carnitine supplementation for, S4:4-12  
in dialysis-related carnitine disorder, 868-876, S4:13-26  
in ESRD, levocarnitine therapy for, S4:35-43
- Cardiopulmonary bypass  
bleeding complications, chronic kidney disease and, 84-89  
during hemodialysis, outcome/complications of, 1247-1256  
predictors of ARF after, 76-83
- Cardiovascular disease (CVD)  
atherosclerotic, dyslipidemia and, S3:22-24  
in ESRD, hyperhomocysteinemia and, S1:89-95  
heart failure as cause for hospitalization in chronic dialysis patients, 1267-1277  
homocysteine in uremia and, S1:123-126  
morbidity in hemodialysis, *N*-acetylcysteine effect on homocysteine and, 442-446  
mortality in hemodialysis  
hypertension and, 814-821  
intima-media thickness of carotid artery and, S1:76-79  
vascular calcifications and, S1:96-99  
prediction, soluble Fas and, 1043-1051  
risk, iron therapy and, S5:18-25  
treating complications in chronic kidney disease, S5:11-17  
valvular, calcium-phosphate imbalance in HD and, 411-421
- Carnitine. *See also* Levocarnitine  
in fatty acid metabolism, S4:4-12  
supplementation, for hemodialysis, S1:116-122  
in understanding dialysis-related disorders, S4:1-3
- Carotid atherosclerosis, apoE polymorphism, eNOS polymorphism and, 822-832
- Case-mix factors, influence on incident dialysis patient survival, 149-161
- Caspases, regulation of apoptosis, allograft rejection and, 1140-1154
- CD59 erythrocyte expression, rEPO and, 179-185
- CD80, in crescentic glomerulonephritis, 950-961
- CD86, in crescentic glomerulonephritis, 950-961
- Cell-surface molecules, in crescentic glomerulonephritis, 950-961
- Centers for Medicare & Medicaid Services, URR and hematocrit values compared with different data systems, 433-441
- Central venous pressure, dialysis-related hypotension and, 807-813
- Chemokine receptors, in progressive renal diseases, S1:15-18
- Chemokines, in progressive renal diseases, S1:15-18
- CHF. *See* Congestive heart failure
- Children  
*ATP6B1* gene mutations in autosomal recessive distal renal tubular acidosis, 238-243  
estimating proteinuria in, 760-766  
with Henoch-Schönlein nephritis, group A streptococcal antigen in, 366-370  
with idiopathic nephrotic syndrome, metabolic bone disease and, 1163-1169  
infants, continuous renal replacement therapy for, 984-989  
with lupus nephritis, renal transplantation for, 455-463  
with nephrotic syndrome, long-course prednisolone for, 155-1162  
organ transplant recipients  
acute myelo-monocytic infiltrate in lower esophagus, E16  
quantitative EBV-tissue PCR in, 212-219  
vascular function in, 684-691

- steroid-sensitive nephrotic syndrome, long-term complications, 550-557
- Choices for Healthy Outcomes in Caring for End-Stage Renal Disease Cohort Study, prognostic importance of comorbidity, 149-161
- Cholesterol
- intermediate-density, as target for lipid-lowering therapy in dialysis patients, S1:72-75
  - low-density. *See* Low-density lipoprotein
  - non-HDL, treating in patients with high triglycerides, S3:53-56
- Chronic kidney disease (CKD)
- ambulatory GFR measurement with cold iohalamate, 752-759
  - bleeding complications after coronary artery bypass surgery and, 84-89
  - cardiovascular complications in, S5:11-17
  - carnitine supplementation, S4:4-12
  - with dyslipidemia, therapeutic lifestyle changes for, S3:68-70
  - establishing programs to improve patient outcomes, 903-924
  - K/DOQI Outcome Quality Initiative guidelines and, S5:3-10
  - obesity at time of renal transplantation and, 480-487
  - prevalence, 1-12
  - prevention, early referral and, 505-507
  - progression, S1:3-7
- Chronic renal failure (CRF). *See also* End-stage renal disease
- carnitine supplementation, S4:4-12
  - chemokines and chemokine receptors in, S1:15-18
  - daytime sleepiness in, 403-410
  - dialysis-related carnitine disorder in, S13-26
  - homocysteine in, S1:123-126
  - liver metabolism in, S1:127-132
  - patient functionality on maintenance HD, levocarnitine and, S4:44-48
  - quality of life, socioeconomic status and, 186-195
  - reciprocal creatinine slope, effects of low-protein diet with oral carbon adsorbent, S1:35-37
  - residual renal function, circulating inflammatory markers and, 1212-1218
  - rHuEPO-hyporesponsive hemodialysis patients, CD34+ cells in, 624-636
  - with rHuEPO hyporesponsiveness, levocarnitine for, S4:27-34
  - risk, advanced glycation end products and, S1:52-56
  - secondary hyperparathyroidism, new treatment strategies for, S1:100-103
  - tryptophan metabolism, effect of oral adsorbent on, S1:38-41
  - very late stage, low-protein diet for, S1:31-34
- Churg-Strauss angiitis, 5-year retrospective study, 776-784
- Cidofovir, Fanconi syndrome induction and, 292-309
- Cirrhotic patients, assessing renal function in, 269-278
- Cisplatin, Fanconi syndrome induction and, 292-309
- CKD. *See* Chronic kidney disease
- Clostridium difficile* colitis, with hemolytic uremic syndrome, E14
- CML. *See* Ne-(Carboxymethyl)lysine
- C<sub>2</sub> monitoring of drug interaction, in renal transplant patient, 493-496
- Cochrane Renal Group Report
- December 2002 ongoing trials, 884-890
  - published trials, 884-890
- Cockcroft-Gault equation, in chronic kidney disease prediction, 1-12
- Comorbidity
- in chronic kidney disease, outcome improvement for, 903-924
  - influence on incident dialysis patient survival, 149-161
  - medication-related problems in ambulatory hemodialysis and, 386-393
  - prognostic importance in chronic dialysis, 149-161
- Complementary DNA array, AST-120 effects on gene expression in uremia, S1:8-14
- Complement receptor 1, rHuEPO treatment and, 179-185
- Complement regulatory proteins, rHuEPO and, 179-185
- Congenital anomalies, with von Hippel-Lindau gene mutation and bilateral pheochromocytomas, E3
- Congestive heart failure (CHF)
- diagnosis, BNP and renal function in, 571-579
  - levocarnitine therapy for, S4:35-43
- Conjugated bile acid replacement therapy, for short bowel syndrome, 230-237
- Continuous ambulatory peritoneal dialysis (CAPD)
- advanced glycation end product formation during, S1:57-60
  - culture-negative peritonitis, pancreaticoduodenocystotomy leak of pancreas transplant and, E19
  - peritoneal dysfunction, role of growth factors and AGEs in, S1:61-67
  - secondary fecal incontinence, E2
- Continuous renal replacement therapy (CRRT), for infants, 984-989
- Continuous venovenous hemodiafiltration, and hemodialysis for iodine toxicity, 702-708
- Coronary artery bypass graft. *See* Cardiopulmonary bypass
- Coronary artery calcification, chronic inflammation in peritoneal dialysis for ESRD, 203-211
- Corticosteroid toxicity, in long-course prednisolone regimens for children with nephrotic syndrome, 1155-1162
- C-reactive protein, outcome prediction in pauci-immune necrotizing glomerulonephritis, 29-37
- Creatine, in cirrhotic patients, 269-278
- Creatinine
- in cirrhotic patients, 269-278
  - in CRF, effects of low-protein diet with oral carbon adsorbent on, S1:35-37
  - diabetic nephropathy progression and, 13-21
  - outcome prediction in pauci-immune necrotizing glomerulonephritis, 29-37
- Creatinine clearance
- in antiphospholipid syndrome, 1205-1211
  - in cirrhotic patients, 269-278
  - improvement after PD prescription change, 840-848
  - in US population, 1-12
- Crescentic glomerulonephritis
- CD80 and CD86 in, 950-961
  - stem cell factor and, 785-795

- Crohn's disease, IgA antglomerular basement membrane nephritis and, 1097-1109
- CRRT (continuous renal replacement therapy), for infants, 984-989
- Cryoglobulinemia, antglomerular basement membrane nephritis with Crohn's disease and, 1097-1109
- CVD. *See* Cardiovascular disease
- Cyclin-dependent kinase inhibitor genes, in aging kidney and chronic allograft nephropathy, 1303-1313
- Cyclosporine
- interaction with Orlistat in renal transplant patient, 493-496
  - for post-rHuEPO pure red blood cell aplasia, 692-695
  - thrombotic microangiopathy after renal transplant and, 471-479
- Cytokines. *See also specific cytokines*
- chronic inflammation in ESRD PD patients and, 203-211
  - circulating levels, residual renal function in CRF and, 1212-1218
  - proinflammatory, acute renal failure of septic shock and, 62-75
- Cytotoxic agents, for proteinuria in IgA nephropathy, 1129-1139
- Databases, URR and hematocrit value comparisons, 433-441
- Daytime sleepiness. *See* Sleepiness, daytime
- ddl, Fanconi syndrome induction and, 292-309
- Decay accelerating factor, rHuEPO and, 179-185
- 3-Deoxyglucosone
- cardiovascular risk and, S1:52-56
  - formation during CAPD, S1:57-60
- Depression
- and malnutrition in chronic hemodialysis patients, 1037-1042
  - in new dialysis patients, 105-110
  - treatment, for new dialysis patients, 105-110
- Diabetes mellitus. *See also* Diabetic nephropathy
- acute muscle infarction in dialysis patients, 1322-1326
  - acute renal failure with nephrotic syndrome in, 1327-1333
  - amputation risk for hemodialysis patients, 162-170
  - care, provision and outcome in hemodialysis patients, 125-131
  - in chronic kidney disease prediction, 1-12
  - chronic renal transplant dysfunction risk and, 859-867
  - with ESRD, assessing glycemic control in, 523-531
  - hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89-95
  - with hypertension, protein intake, microalbuminuria and, 580-587
  - hypouricemia in inpatient hospital-based facility, 1225-1232
  - immuno-unreactive albumin in urine, 336-342
  - left ventricular dysfunction in ESRD and, 1016-1025
  - prevalence of peripheral arterial calcification in ESRD and, 140-148
  - protein intake, microalbuminuria and, 580-587
- type 1
- long-term survival after kidney-pancreas transplant, 464-470
  - susceptibility to diabetic nephropathy, 1189-1194
- type 2
- drug interaction in renal transplant patient, 493-496
  - interrelated predictors of progression in, 13-21
  - recent management advances, S1:22-25
  - weight loss for overweight chronic proteinuric nephropathy, 319-327
- Diabetic nephropathy
- AGE nephrotoxicity, new therapies for, S1:42-47
  - effect of oral adsorbent and with low-protein diet on creatinine slope, S1:35-37
  - OPB-9195 amelioration of glomerular lesions in, S1:68-71
  - progression, S1:19-21
  - ACE gene polymorphism and, 943-949
  - losartan and, S1:22-25
  - smoking and albuminuria as predictors of, 13-21
  - susceptibility in type 1 diabetes, MTHFR gene polymorphism and, 1189-1194
  - with uncontrolled hypertension, renal artery stenosis in, 351-359
- Dialysis. *See also* Hemodialysis; Peritoneal dialysis
- atherosclerosis in, soluble Fas as predictor of, 1043-1051
  - carnitine supplementation, S4:4-12
  - for diabetic ESRD patients, glycemic control in, 523-531
  - exercise counseling by nephrologists, 171-178
  - hepatitis B viremia in, determination of viral load in, 1278-1285
  - levocarnitine therapy for, S4:4-12
  - modality selection, barriers for self-care dialysis in ESRD, 380-385
  - monitoring, estimation of delivered dose by UV absorbance, 1026-1036
  - new patients, depression in, 105-110
  - prevalence of peripheral arterial calcification in ESRD and, 140-148
  - survival, obesity and, 925-932
- Dialysis dose
- for dialysis patients, protein intake and, S1:133-136
  - estimation by UV absorbance, 1026-1036
- Dialysis Morbidity and Mortality Study Wave 2
- heart failure as cause for hospitalization in chronic dialysis patients, 1267-1277
  - pre-ESRD referral timing and, 310-318
  - sedentary behavior effect on dialysis patient survival, 447-454
- Dialysis Morbidity and Mortality Study Waves 3 and 4
- amputation risk factors, 162-170
  - time of day for hemolysis, survival and, 796-806
- Dialysis Outcomes and Practice Patterns Study, health-related quality of life for ESRD hemolysis patients of different ethnicities, 605-615
- Dialysis-related carnitine disorder
- L-carnitine for, 868-876
  - evolving understanding of, S4:1-3
  - levocarnitine pharmacology and, S13-26
- Diet. *See also* Nutrition
- low-calorie, for overweight chronic proteinuric nephropathy patients, 319-327
  - low-protein. *See* Low-protein diet
- DNA hybridization, determination of HBV viral load in dialysis patients, 1278-1285

- DNA sequence variants, advanced diabetic nephropathy and, 22–28
- Drug interaction, in renal transplant patient, 493–496
- Dual dialyzers, comparison in parallel and series, 1008–1015
- Dual x-ray absorptiometry, body fat mass in hemodialysis, S1:137–141
- Duplex ultrasound of vasculature, gender differences in, 429–432
- Dyslipidemia  
assessment, K/DOQI Clinical Practice guidelines for, S3: 22–38  
chronic renal transplant dysfunction risk and, 859–867  
prevalence, S3:26–29  
treatment, K/DOQI Clinical Practice guidelines for, S3: 39–58
- EBV (Epstein-Barr virus), quantitative tissue PCR in pediatric solid organ recipients, 212–219
- Elderly renovascular disease, blood pressure and renal function in, 990–996
- ELISA tissue EBV, for pediatric solid organ recipients, 212–219
- Endothelial cells  
fluvastatin effects on hypercholesterolemic renal transplant recipients, 1088–1096  
progenitors, in vessel repair, allograft survival and, 1140–1154  
survival in predicting allograft acceptance/function, 1140–1154
- Endothelial dysfunction  
and left ventricular hypertrophy in chronic hemodialysis, 616–623  
in pediatric renal transplant recipients, 684–691
- Endothelial nitric oxide synthase gene polymorphism  
carotid atherosclerosis and, 822–832  
in polycystic kidney disease 1, 90–94
- Endothelin-1, in uremic kidney, AST-120 effects on, S1: 8–14
- Endothelium growth phenotype, allograft survival and, 1140–1154
- End-stage renal disease (ESRD)  
anemia, effect of hemoglobin variability in, 111–124  
cardiovascular disease  
hyperhomocysteinemia in, S1:89–95  
levocarnitine therapy for, S4:35–43  
carnitine supplementation, S4:4–12  
chronic hemodialysis, deselection for, 723–732  
depression and, 105–110  
with diabetes, MTHFR gene polymorphism and, 1189–1194  
diabetic nephropathy progression  
losartan and, S1:22–25  
smoking, albuminuria and, 13–21  
dialysis modality effect on HIV-associated nephropathy survival, 1060–1064  
dialysis-related carnitine disorder in, S13–26  
erythropoietin therapy in hemodialysis patients, vitamin C and, 1233–1239  
health-related quality of life  
in hemodialysis patients of different ethnicities, 605–615  
population-based study of, 596–604  
hemodialysis-dependent, early onset menopause and postmenopausal hormone therapy, 643–650  
with HIV infection, management of, 279–291  
impact of pre-ESRD referral timing, 310–318  
intima-media thickness of carotid artery in, S1:76–79  
K/DOQI Outcome Quality Initiative guidelines and, S5: 3–10  
kidney-pancreas transplant for type 1 diabetes mellitus and, 464–470  
maintenance hemodialysis, patient functionality, levocarnitine and, S4:44–48  
peripheral arterial calcification in, 140–148  
peripheral arterial disease, nocturnal hemodialysis for, 225–229  
in PR3-ANCA vasculitis, proinflammatory IL-1 $\beta$ /IL-1ra genotype and, 933–942  
quality of life, socioeconomic status and, 186–195  
with rHuEPO hyporesponsiveness, levocarnitine for, S4: 27–34  
risk factors, in pauci-immune necrotizing glomerulonephritis, 29–37  
self-care dialysis, barriers toward, 380–385  
subclinical left ventricular dysfunction, risk factors for, 1016–1025  
USRDS 2002 Annual Data Report, S2:1–253  
vascular calcifications in, S1:96–99
- Energy intake, balancing dialysis dose and protein intake for dialysis patients, S1:133–136
- Eosinophil-rich interstitial infiltrate, in allograft dysfunction, 1116–1121
- Epidemiology, of predialysis patients, retrospective chart review for, 49–61
- EPO. *See* Erythropoietin
- Epoetin. *See* Erythropoietin
- Epstein-Barr virus (EBV), quantitative tissue PCR in pediatric solid organ recipients, 212–219
- Erythroid progenitors, in hyporesponsive rHuEPO CRF patients, 624–636
- Erythropoietin (EPO)  
effect of hemoglobin variability on, 111–124  
recombinant human. *See* Recombinant human erythropoietin  
response in hemodialysis patients, vitamin C and, 1233–1239
- Escherichia coli* O157:H7 bacteremia, nondiarrheal hemolytic uremic syndrome with UTI, E4
- ESRD. *See* End-stage renal disease
- Estrogen  
early menopause and hormone use in dialysis-dependent women, 643–650  
in postmenopausal hemodialysis-dependent women, 1240–1246
- Ethnicity, health-related quality of life for ESRD hemolysis patients, 605–615
- Ethyl-icosapentatel, in lipid-lowering therapy for lipoprotein glomerulopathy, 244–249
- Exercise counseling, by nephrologists, 171–178
- Fanconi syndrome  
compared with V $\kappa$ l light chain in myeloma tubulopathy, 497–504

- drug-induced, 292–309
- Fatty acid metabolism, carnitine in, S4:4–12
- Fear, as barrier for self-care dialysis in ESRD, 380–385
- Fecal fat excretion, in short bowel syndrome, 230–237
- Fecal incontinence, secondary to CAPD, E2
- Fechtner syndrome, nonmuscle myosin IIA abnormality in, 95–104
- Females
- acute renal failure after open-heart surgery, 724–751
  - dialysis-dependent, early onset menopause in, 643–650
  - postmenopausal. *See* Postmenopausal women
- Fenofibrate, for lipoprotein glomerulopathy, 244–249
- Ferritin, prediction of ARF after cardiac surgery and, 76–83
- Fish gallbladder ingestion, nephrotoxic, 220–224
- Fish oils, for proteinuria in IgA nephropathy, 1129–1139
- Flow-mediated dilatation
- endothelial dysfunction and LVH in chronic hemodialysis, 616–623
  - in pediatric renal transplant recipients, 684–691
- Fluoroquinolones, renal parenchymal malacoplakia causing acute renal failure, E21
- 18-F-Fluorodeoxyglucose PET, diagnosis of renal and hepatic cysts in ADPKD, E22
- Fluvastatin, for hypercholesterolemic renal transplantation recipients, 1088–1096
- Focal segmental glomerulosclerosis (FSGS)
- in antiphospholipid syndrome, 1205–1211
  - familial, clinical, histopathologic and genetic studies of, 1170–1178
  - in IgM nephropathy, 343–350
  - membranous nephropathy prognosis and, 38–48
  - nephronopenic, glomerular basement membrane length to podocyte ratio, 1179–1188
  - outcome prediction, IgG excretion and, 328–335
  - recurrence after pediatric renal transplantation, 1314–1321
- Frasier syndrome, Alport syndrome-like basement membrane changes in, 1110–1115
- Fructosamine, in diabetic ESRD patients, 523–531
- FSGS. *See* Focal segmental glomerulosclerosis
- Fumaric acid, Fanconi syndrome induction and, 292–309
- Functional well-being, in dialysis-related carnitine disorder, 868–876
- Galactosylation abnormalities, in IgA nephropathy, 558–564
- Gamma-glutamyl transpeptidase (GGTP), prediction of ARF after allograft ischemic injury, 1074–1087
- Gene expression, lipogenic, in triglyceride biosynthesis in uremia, S1:84–88
- Gene for  $\alpha$ -actinin 4 (ACTN4), in focal segmental glomerulosclerosis, 1170–1178
- Gene for steroid resistant nephrotic syndrome 2, in FSGS, 1170–1178
- Gene mutations, distal renal tubular acidosis and deafness in child and, 238–243
- Gene polymorphisms
- carotid atherosclerosis and, 822–832
  - diabetic nephropathy and, 22–28
  - IgA nephropathy progression and, 371–379
  - polycystic kidney disease 1 and, 90–94
- Genetic studies, of familial focal segmental glomerulosclerosis, 1170–1178
- GFR. *See* Glomerular filtration rate
- Glomerular basement membrane
- length in nephropenic FSGS, 1179–1188
  - thickness in IgA nephropathy, 558–564
- Glomerular filtration rate (GFR)
- ambulatory measurement with cold iohalamate, 752–759
  - and BNP in congestive heart failure diagnosis, 571–579
  - in chronic kidney disease
    - bleeding complications after CABG and, 84–89
    - circulating inflammatory markers and, 1212–1218
    - prediction, 1–12  - in cirrhotic patients, 269–278
  - decline, high urine volume, low urine osmolality and, 962–971
  - effects of dietary AGEs on, S1:48–51
  - K/DOQI Outcome Quality Initiative Guidelines and, S5:3–10
  - renal outcome in ANCA-associated glomerulonephritis and, 532–538
- Glomeruli, abnormal, outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37
- Glomerulonephritis
- ANCA-associated, index for renal outcome in, 532–538
  - chronic, effect of oral adsorbent and with low-protein diet on creatinine slope, S1:35–37
  - inherited, nonmuscle myosin IIA abnormality in, 95–104
  - pauci-immune necrotizing, clinicopathologic predictors for, 29–37
- Glomerulosclerosis
- in diabetic nephropathy, TGF- $\beta$  polymorphism and, 22–28
  - focal segmental. *See* Focal segmental glomerulosclerosis
- Glucose, blood, in uremic diabetic patients, 523–531
- Glucose degradation products, formation during CAPD, S1:57–60
- Glucosuria
- in drug-induced Fanconi syndrome, 292–309
  - in patients admitted to inpatient hospital-based facility, 1225–1232
- Glue sniffing, Fanconi syndrome and, 292–309
- Glycated proteins, in diabetic ESRD patients, 523–531
- Glycation profile, in immunoglobulin A nephropathy, 558–564
- Graft infection, *Aspergillosis*, after cadaveric renal transplant, 488–492
- Granulomatous interstitial nephritis
- case study, 714–719
  - levofloxacin-induced, E7
- Growth factors, in peritoneal dysfunction in CAPD patients, S1:61–67
- HD. *See* Hemodialysis
- Heart failure
- as cause for hospitalization in chronic dialysis patients, 1267–1277
  - congestive. *See* Congestive heart failure
- HELP study. *See* Hemodialysis and Estrogen Levels in Postmenopausal Patients (HELP)
- Hematocrit
- comparison in different data systems, 433–441



- effect of hemoglobin variability on anemia management and, 111-124
- outcome prediction in pauci-immune necrotizing glomerulonephritis, 29-37
- Hematologic neoplasms, hypouricemia in inpatient hospital-based facility, 1225-1232
- Hematuria
- in IgM nephropathy, 343-350
  - prevalence among Zuni Indians, 1195-1204
- Hemodialysis (HD)
- access. *See* Vascular access
  - for acute renal failure after accidental perchloroethylene ingestion, E11
  - ambulatory, medication-related problems in, 386-393
  - amputation risk factors for, 162-170
  - arteriovenous fistula blood flow and resistance during, 132-139
  - atherosclerotic cardiovascular disease, dyslipidemia and, S3:22-24
  - body fat mass in, S1:137-141
  - cardiac valvular disease, calcium-phosphate imbalance in, 411-421
  - during cardiopulmonary bypass, outcome/complications of, 1247-1256
  - cardiovascular disease mortality, intima-media thickness of carotid artery and, S1:76-79
  - carnitine supplementation, S1:116-122
  - carotid atherosclerosis, gene polymorphisms and, 822-832
  - chronic
    - anemia in, safety of high-dose SFGC for, 651-657
    - deselection for, 723-732
    - heart failure as cause for hospitalization in, 1267-1277
    - L/VH and endothelial dysfunction in, 616-623
    - malnutrition and depression in, 1037-1042
    - 22-oxa-1,25-dihydroxyvitamin D<sub>3</sub> for, S1:108-111
    - comparison of dual dialyzers in parallel and series, 1008-1015
    - and continuous venovenous hemodiafiltration for iodine toxicity, 702-708
  - daily
    - for massive uremic tumoral calcinosis, E12
    - nutrition and, S1:112-115
    - daytime sleepiness in, 394-402
  - for diabetic patients, provision and outcomes of care for, 125-131
  - diffuse alopecia caused by tinzaparin, E15
  - dose. *See* Dialysis dose
  - erythropoietin response, vitamin C and, 1233-1239
  - for ESRD
    - effect of socioeconomic status on quality of life, 186-195
    - health-related quality of life in patients of different ethnicities, 605-615
    - negative attitudes toward self-care and, 380-385
    - survival, HIV-associated nephropathy and, 1060-1064
    - estimation of delivered dose by UV absorbance, 1026-1036
    - evening shift, survival improvement and, 796-806
    - homocysteine levels, *N*-acetylcysteine and, 442-446
    - hydration status, brain natriuretic peptide and, 1257-1266
    - infection risk, iron therapy and, S5:18-25
    - limb swelling, acute muscle infarction in diabetic patients, 1322-1326
    - lipid-lowering therapy, non-HDL cholesterol as target for, S1:72-75
    - lower body negative pressure, hemodynamic response to, 807-813
    - maintenance, patient functionality, levocarnitine and, S4:44-48
    - morning shift, survival improvement and, 796-806
    - mortality, sedentary behavior and, 447-454
    - nocturnal
      - for lower-extremity peripheral arterial disease, 225-229
      - nutrition and, S1:112-115
    - outcome. *See* Outcome
    - for postmenopausal women, estrogen levels in, 1240-1246
    - predialysis care, retrospective chart review of, 49-61
    - pre-ESRD referral timing and, 310-318
    - QT dispersion, intracellular magnesium and, 196-202
    - rEPO therapy, mechanisms of, 179-185
    - survival, obesity and, 925-932
    - uremic patients, restless legs syndrome IN, 833-839
    - vascular access thrombosis risk, MTHFR gene polymorphism and, 637-642

Hemodialysis and Estrogen Levels in Postmenopausal Patients (HELP)

    - early menopause and hormone use in dialysis-dependent women, 643-650
    - low estrogen in postmenopausal hemodialysis-dependent women, 1240-1246

Hemoglobin

    - A<sub>1c</sub> in diabetic ESRD patients, 523-531
    - predialysis anemia survey, 49-61
    - restless legs syndrome in uremic hemodialysis patients and, 833-839
    - variability, anemia management in ESRD and, 111-124

Hemolytic uremia syndrome (HUS)

    - resolution of thrombocytopenia but not hemolysis after interferon- $\alpha$  withdrawal, E10

Hemolytic uremic syndrome (HUS)

    - with *Clostridium difficile* colitis, E14
    - nondiarrheal, associated with shiga toxin bacteremia and UTI, E4
    - post-renal transplant thrombotic microangiopathy and, 471-479
    - with typhoid fever, 709-713

Henoch-Schönlein nephritis, group A streptococcal antigen in, 366-370

Hepatic cysts, diagnosis by 18-FDG-PET, E22

Hepatitis B, viral load in dialysis population, biological dynamics of, 1278-1285

Hepatitis C-virus-associated tubulointerstitial injury, 767-775

Hepatocyte growth factor, peritoneal dysfunction in CAPD patients and, S1:61-67

Hepatocytes, in chronic renal failure, cytosolic calcium in, S1:127-132

High performance liquid chromatography, albuminuria in diabetes mellitus, 336-342

Histopathology, of familial focal segmental glomerulosclerosis, 1170-1178



- Histoplasmosis, granulomatous interstitial nephritis and, 714-719
- HIV-associated nephropathy with ESRD, dialysis modality effect on survival, 1060-1064
- HIV infection. *See* Human immunodeficiency virus infection
- HMG-CoA reductase inhibitors, for hypercholesterolemic renal transplantation recipients, 1088-1096
- Homocysteine  
cardiovascular disease in ESRD and, S1:89-95  
in hemodialysis, *N*-acetylcysteine and, 442-446  
high, vascular thrombosis risk and, 637-642  
prevalence of peripheral arterial calcification in ESRD and, 140-148  
in uremia, S1:123-126
- Hospitalization, for ESRD hemolysis patients of different ethnicities, 605-615
- Human immunodeficiency virus infection (HIV)  
with ESRD, management of, 279-291  
nephropathy management, 279-291
- HUS. *See* Hemolytic uremic syndrome
- Hydration status, in hemodialysis, brain natriuretic peptide and, 1257-1266
- 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG-CoA inhibitors), non-HDL cholesterol as target for, S1:72-75
- Hyperalbuminemia, hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89-95
- Hyperaminoaciduria, in drug-induced Fanconi syndrome, 292-309
- Hypercalciuria, in drug-induced Fanconi syndrome, 292-309
- Hypercholesterolemia, in renal transplantation recipients, HMG-CoA reductase inhibitors for, 1088-1096
- Hyperhomocysteinemia, cardiovascular disease in ESRD, S1:89-95
- Hyperkalemia, hemodialysis during cardiopulmonary bypass with potassium-rich cardioplegia, 1247-1256
- Hyperoxaluria, in short bowel syndrome, 230-237
- Hyperparathyroidism, secondary  
calcimimetics for, S1:104-107  
in chronic hemodialysis, 22-oxa-1,25-dihydroxyvitamin D<sub>3</sub> for, S1:108-111  
new treatment strategies, S1:100-103
- Hyperphosphatemia, restless legs syndrome in uremic hemodialysis patients and, 833-839
- Hypertension  
in chronic kidney disease prediction, 1-12  
chronic renal transplant dysfunction risk and, 859-867  
control, effect on diabetic nephropathy progression and albuminuria, 13-21  
with diabetes mellitus, protein intake, microalbuminuria and, 580-587  
endothelial dysfunction and LVH in chronic hemodialysis, 616-623  
idiopathic membranous glomerulonephritis prognosis and, 38-48  
left ventricular dysfunction in ESRD and, 1016-1025  
mortality in hemodialysis and, 814-821  
pediatric renal transplant recipients, vascular function in, 684-691  
pre-dialysis, survival of hemodialysis patients and, 814-821  
protein intake, microalbuminuria and, 580-587  
and renovascular disease and renal function in elderly, 990-996  
uncontrolled with diabetic nephropathy and renal artery stenosis, 351-359
- Hypertriglyceridemia  
treatment, K/DOQI Clinical Practice guidelines for, S3:39-41  
in uremia, S1:84-88
- Hypoalbuminemia in peritoneal dialysis patients, peritonitis prediction and, 664-669
- Hypokalemia  
in drug-induced Fanconi syndrome, 292-309  
in patients admitted to inpatient hospital-based facility, 1225-1232
- Hypophosphatemia, in patients admitted to inpatient hospital-based facility, 1225-1232
- Hypotension  
dialysis-related, lower body negative pressure in HD, 807-813
- Hypotension  
intradialytic, dialysis-related carnitine disorder and, 868-876
- Hypouricemia, in inpatient hospital-based facility, 1225-1232
- I-cell disease, foamy podocytes in, 891-896
- Ichthyotoxism, from fish gallbladder ingestion, 220-224
- Idiopathic glomerulopathies  
clinical picture and long-term prognosis, 343-350  
progression and proteinuria, atorvastatin effects on, 565-570
- Idiopathic membranous glomerulonephritis (IMGN)  
PECAM-1 and angiogenic factor expression in, 360-365  
prognosis, focal segmental glomerulosclerosis and, 38-48
- Idiopathic nephrotic syndrome, metabolic bone disease risk in children and, 1163-1169
- Idiopathic pauci-immune glomerulonephritis, ANCA antigen specificity in, 539-549
- Ifosfamide, Fanconi syndrome induction and, 292-309
- IgA antglomerular basement membrane nephritis, Crohn's disease and, 1097-1109
- IgA nephropathy. *See* Immunoglobulin A nephropathy
- IgM nephropathy, clinical picture and long-term prognosis, 343-350
- Iliac artery pseudoaneurysm, after ca-lavetric renal transplant, 488-492
- IMGN. *See* Idiopathic membranous glomerulonephritis
- Imidazolone  
formation during CAPD, S1:57-60  
peritoneal dysfunction in CAPD patients and, S1:61-67
- Immune-complex mediated disease, Henoch-Schönlein nephritis as, 366-370
- Immunoglobulin A nephropathy  
glycation profile in, 558-564  
low-dose prednisolone for, 972-983  
progression, INF- $\gamma$  and IL-4 gene polymorphisms and, 371-379  
therapeutic options, survey of, 1129-1139

- Immunoglobulin G, urinary excretion in predicting FSGS outcome, 328-335
- Immunohistochemistry, hepatitis C virus-associated tubulointerstitial injury, 767-775
- Immunosuppression  
 adenovirus infection of renal allograft and, 696-701  
 calcineurin-inhibitor-based, thrombotic microangiopathy after, 471-479  
 influence on dyslipidemia, S3:36  
 post-renal transplant prediction of nonmelanoma skin cancer, 676-683
- Index of Coexistent Disease (ICED), changes over chronic dialysis therapy, prognostic importance of, 149-161
- Indoxyl sulfate  
 binding, effect of tryptophan metabolism in uremia, S1:38-41  
 removal, effects on gene expression in uremic kidney, S1:8-14  
 serum levels in hemodialysis, *bifidobacterium* and, S1:142-145
- Infants, continuous renal replacement therapy for, 984-989
- Inferior vena caval diameter, hydration status in hemodialysis and, 1257-1266
- Inflammation  
 chronic, in ESRD PD patients, coronary artery calcification and, 203-211  
 hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89-95  
 soluble Fas as predictor of atherosclerosis in ESRD, 1043-1051
- Inflammatory bowel disease, IgA antglomerular basement membrane nephritis and, 1097-1109
- Inflammatory markers, residual renal function in CRF and, 1212-1218
- Inherited glomerular disease  
 nonmuscle myosin IIA abnormality in, 95-104  
 recurrence of FSGS after pediatric renal transplant, 1314-1321
- In situ hybridization, hepatitis C virus-associated tubulointerstitial injury, 767-775
- Insulin resistance  
 chronic renal transplant dysfunction and, 859-867  
 left ventricular hypertrophy in type 1 PKD and, 1219-1224
- Interferon- $\alpha$  withdrawal, resolution of thrombocytopenia in HUS, E10
- Interferon- $\gamma$  gene polymorphism, IgA nephropathy progression and, 371-379
- Interleukin-6  
 acute renal failure with septic shock and, 62-75  
 prediction of ARF after allograft ischemic injury, 1074-1087
- Interleukin-8, prediction of ARF after allograft ischemic injury, 1074-1087
- Interleukin-4 gene polymorphism, immunoglobulin A nephropathy progression and, 371-379
- Interleukin-1 proinflammatory genotype, in proteinase 3-ANCA vasculitis, 933-942
- Interleukin-1 receptor antagonist, proinflammatory genotype in proteinase 3-ANCA vasculitis, 933-942
- Intermediate-density lipoprotein cholesterol, as target for lipid-lowering therapy in dialysis, S1:72-75
- Interstitial fibrosis  
 chemokines and chemokine receptors in, S1:15-18  
 outcome prediction in pauci-immune necrotizing glomerulonephritis, 29-37
- Interstitial nephritis, adenovirus infection of renal allograft, 696-701
- Inulin  
 in cirrhotic patients, 269-278  
 clearance, compared with iothalamate clearance in CKD, 752-759
- Iodine toxicity, hemodialysis and continuous venovenous hemodiafiltration for, 702-708
- Iothalamate clearance technique, for GFR measurement in chronic kidney disease, 752-759
- Iron, in atherosclerosis, S1:80-83
- Iron deficiency anemia, in chronic hemodialysis, high-dose sodium ferric gluconate complex for, 651-657
- Iron dextran  
 compared to high-dose SFGC infusion for chronic hemodialysis patients, 651-657  
 safety profile, S5:18-25
- Iron gluconate, in chronic hemodialysis, safety of, 651-657
- Iron sucrose  
 safety in chronic hemodialysis, 651-657  
 safety profile, S5:18-25
- Iron therapy  
 effect of hemoglobin variability on, 111-124  
 intravenous, safety in, S5:18-25  
 safety of high-dose SFGC infusion for chronic hemodialysis patients, 651-657
- Ischemic nephropathy, blood pressure and renal function in elderly, 990-996
- Japanese patients, gene polymorphisms and IgA nephropathy progression, 371-379
- K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease  
 assessment of dyslipidemias, S3:22-38  
 development, methods for, S3:17-21  
 evidence, S3:21  
 intended users, S3:15-17  
 methods for review of articles, S3:61-69  
 rationale for, S3:11-13  
 research recommendations, 59-60, S3:21  
 scope, S3:14-15  
 target population, S3:13-14  
 therapeutic lifestyle changes for CKD, S3:69-70  
 treatment of dyslipidemias, S3:39-58  
 updates, anticipated, S3:17
- K/DOQI Outcome Quality Initiative guidelines  
 iron therapy safety, S5:18-25  
 meeting challenges of, S5:3-10
- Keto acids, metabolic effect in CRF patients on low-protein diet and erythropoietin, S1:26-30
- Kidney disease. *See also specific kidney diseases*  
 prevalence among Zuni Indians with/without diabetes, 1195-1204
- Kidney function tests, in cirrhotic patients, 269-278

- Kidney-pancreas transplant  
de novo thrombotic microangiopathy and, 471-479  
pancreaticoduodenocystostomy leak, culture-negative peritonitis and, E19
- Kidney senescence, chronic allograft nephropathy, cyclin-dependent kinase inhibitor genes and, 1303-1313
- Knowledge barrier, for self-care dialysis in ESRD, 380-385
- Kt/V, improvement after peritoneal dialysis prescription change, 840-848
- Lactate dehydrogenase, prediction of ARF after allograft ischemic injury, 1074-1087
- L-Carnitine. *See* Levocarnitine
- Lean body mass, in hemodialysis patients, S1:137-141
- Left ventricular dysfunction, subclinical, risk factors in ESRD, 1016-1025
- Left ventricular hypertrophy (LVH)  
and endothelial dysfunction in chronic hemodialysis, 616-623  
risk, advanced glycation end products and, S1:52-56  
in type 1 PKD, insulin resistance and, 1219-1224
- Left ventricular mass  
insulin resistance in polycystic kidney disease type 1 and, 1219-1224  
left ventricular dysfunction in ESRD and, 1016-1025
- Leptin, chronic inflammation in ESRD PD patients and, 203-211
- Levocarnitine  
for chronic hemodialysis patients, S4:4-12  
for dialysis-related carnitine disorder, 868-876  
for myocardial dysfunction, S4:35-43  
patient functionality in maintenance hemodialysis, S4:44-48  
pharmacology, dialysis-related carnitine disorder and, S13-26
- Levofloxacin, induction of granulomatous interstitial nephritis, E7
- Light-and-heavy-chain deposition disease, case study, 508-517
- Limb swelling, in hemodialysis patients, diabetic muscle infarction and, 1322-1326
- Lipid-lowering therapy  
in dialysis patients, non-HDL cholesterol as target for, S1:72-75  
for lipoprotein glomerulopathy, 244-249
- Lipid metabolism  
carnitine supplementation in hemodialysis, S1:116-122  
in liver of chronic renal failure patient, S1:127-132
- Lipidoses, foamy podocytes in, 891-896
- Lipid peroxidation, carnitine in, S4:4-12
- Lipogenesis, in development of uremic hyperlipidemia, S1:84-88
- Lipoprotein(a), prevalence of peripheral arterial calcification in ESRD and, 140-148
- Lipoprotein glomerulopathy, intensive lipid-lowering therapy for, 244-249
- Liver disease, assessing renal function in, 269-278
- Liver function tests, in cirrhotic patients, 269-278
- Liver metabolism, in chronic renal failure, S1:127-132
- L-Lysine, Fanconi syndrome and, 292-309
- Losartan, diabetes nephropathy progression and, S1:22-25
- Low-calorie diet, for overweight chronic proteinuric nephropathy patients, 319-327
- Low-density lipoprotein (LDL)  
calculation, Friedewald formula for, S3:34-35  
high, K/DOQI Clinical Practice guidelines for treating, S3:-5341  
oxidation in atherosclerosis, iron and, S1:80-83  
as target for lipid-lowering therapy in dialysis patients, S1:72-75
- Lower body negative pressure in hemodialysis, hemodynamic response to, 807-813
- Low-protein diet  
control of chronic rejection in kidney transplant recipients, S1:146-152  
with keto acids and erythropoietin for CRF patients, S1:26-30  
with oral carbon adsorbent, effect on creatinine slope in CRF, S1:35-37  
for very late stage CRF, S1:31-34
- Lupus anticoagulant, in antiphospholipid syndrome, 1205-1211
- Lupus nephritis, in children, renal transplantation for, 455-463
- Lymphangioliomyomatosis, renal angiomyolipoma and, 877-883
- Lymphokines. *See also specific lymphokines*  
prediction of ARF after allograft ischemic injury, 1074-1087
- Macromolecule hypomethylation, homocysteine in uremia, S1:123-126
- Macrophages, in crescentic glomerulonephritis, 950-961
- Magnesium, intracellular, QT dispersion in hemodialysis patients and, 196-202
- Malacoplakia, renal parenchymal, causing acute renal failure, E21
- Male vasculature, arteriovenous fistula placement and, 429-432
- Malnutrition  
and depression in chronic hemodialysis patients, 1037-1042  
hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89-95
- Mast cells, crescentic glomerulonephritis and, 785-795
- Maxacalcitol, for secondary hyperparathyroidism, S1:100-103
- Maximal glomerular hypertrophy, in nephropenic focal segmental glomerulosclerosis, 1179-1188
- MCD. *See* Minimal change disease
- MDRD. *See* Modification of Diet in Renal Disease
- Mean arterial pressure. *See* Blood pressure
- Mechanical stretch, diabetic nephropathy progression and, S1:19-21
- Mediastinal irrigation, dialytic therapy for iodine toxicity from, 702-708
- Medical Outcomes Study 30-Item Short Form  
health-related quality of life in ESRD, 596-604  
impact of socioeconomic status on ESRD quality of life, 186-195  
prediction of morbidity/mortality in dialysis patients, 1286-1292

- Medicare  
 effect of hemoglobin variability on anemia management and, 111-124  
 national EPO reimbursement policy, 254-258  
 Medication-related problems, in ambulatory hemodialysis, 386-393  
 Membranous nephropathy  
 in antiphospholipid syndrome, 1205-1211  
 caused by skin whitening cream, 250-253  
 prognosis, focal segmental glomerulosclerosis and, 38-48  
 Meningeal cysts, multiple thoracic paraspinal in ADPKD, E8  
 Menopause. *See also* Postmenopausal women  
 early onset, in dialysis-dependent women, 643-650  
 Mental Component Summary, prediction of morbidity/mortality in dialysis patients, 1286-1292  
 Mental function monitoring, in dialysis patients, 1286-1292  
 Mercaptopurine, Fanconi syndrome induction and, 292-309  
 Mercury poisoning, causing membranous nephropathy, 250-253  
 Mesangial C3 nephropathy, in antiphospholipid syndrome, 1205-1211  
 Mesangial glomerulonephritis, clinical picture and long-term prognosis, 343-350  
 Meta-analysis, of therapeutic options for IgA nephropathy, 1129-1139  
 Metabolic bone disease risk, in children with idiopathic nephrotic syndrome, 1163-1169  
 Metabolic control, in diabetic ESRD patients, 523-531  
 Methyl-3-chromone, Fanconi syndrome induction and, 292-309  
 Methyltetrahydrofolate reductase gene polymorphism  
 susceptibility to diabetic nephropathy in type 1 diabetes and, 1189-1194  
 vascular access thrombosis risk in hemodialysis, 637-642  
 Michaelis-Gutman bodies, renal parenchymal malacoplakia causing ARF, E21  
 Microalbuminuria  
 central fat distribution and, 733-741  
 high-normal blood pressure and, 588-595  
 protein intake in healthy adults and, 580-587  
 $\alpha_1$ -Microglobulin, urinary excretion in predicting FSGS outcome, 328-335  
 Microscopic polyangiitis, proinflammatory IL-1 $\beta$ /IL-1ra genotype and, 933-942  
 Middle molecules, comparison of dual dialyzers in parallel and series, 1008-1015  
 Minimal change disease (MCD)  
 in antiphospholipid syndrome, 1205-1211  
 nephrotic syndrome with acute renal failure in diabetes mellitus, 1327-1333  
 Mitochondriopathy, asymptomatic proteinuria and hearing loss in, 259-264  
 Mitogen-activated protein kinase, progression of diabetic nephropathy, S1:19-21  
 Modification of Diet in Renal Disease (MDRD)  
 GFR estimation equation, 1-12  
 high urine volume and low urine osmolality as risk factors, 962-971  
 Monoclonal immunoglobulin deposition disease (MIDD), case study, 508-517  
 Morbidity, time of day for hemolysis and, 796-806  
 Mortality  
 diabetic nephropathy susceptibility in type 1 diabetes, methyltetrahydrofolate reductase gene polymorphism and, 1189-1194  
 of dialysis patients, sedentary behavior and, 447-454  
 for ESRD hemolysis patients of different ethnicities, 605-615  
 in hemodialysis, hypertension and, 814-821  
 prediction, in ARF of septic shock, tumor necrosis factor- $\alpha$  receptors and, 62-75  
 pre-ESRD referral timing and, 310-318  
 time of day for hemolysis and, 796-806  
 Mucopolidosis type II, foamy podocytes in, 891-896  
 Muscle infarction, limb swelling in diabetic hemodialysis patients and, 1322-1326  
 Muscle weakness, of dialysis-related carnitine disorder, L-carnitine for, 868-876  
 Myeloma tubulopathy, caused by monoclonal V $\kappa$  light chain, 497-504  
 Myelo-monocytic infiltrate, in lower esophagus of pediatric renal transplant recipient, E16  
 Myocardial contractility, dialysis-related hypotension and, 807-813  
 Myocardial Doppler velocity, left ventricular dysfunction in ESRD and, 1016-1025  
 Myocardial infarction, levocarnitine therapy for, S4:35-43  
 Myocarditis, hemolytic uremic syndrome with typhoid fever and, 709-713  
 NAC (*N*-acetylcysteine), plasma homocysteine levels in HD and, 442-446  
 National Health and Nutrition Survey III (NANES III), microalbuminuria and protein intake in healthy adults, 580-587  
 Necrotizing tracheitis, pediatric, EBV load determination for, 212-219  
 Needle phobia, as barrier for self-care dialysis in ESRD, 380-385  
 Nephrectomy, living donors, patient attitudes on, 849-858  
 Nephritis, tubulointerstitial, hepatitis C-virus associated, 767-775  
 Nephritis-associated plasmin receptor, in Henoch-Schönlein nephritis, 366-370  
 Nephrolithiasis, in short bowel syndrome, conjugated bile acid replacement therapy and, 230-237  
 Nephrologists  
 exercise counseling by, 171-178  
 in improving outcome for chronic kidney disease, 903-924  
 Nephrology decision-making, controversies in, 723-732  
 Nephropathy, antiphospholipid antibody-associated, 1205-1211  
 Nephropenia in FSGS, glomerular basement membrane length to podocyte ratio, 1179-1188  
 Nephrotic syndrome  
 with acute renal failure in diabetes mellitus, 1327-1333  
 in children, long-course prednisolone regimens for, 1155-1162  
 idiopathic, metabolic bone disease risk in children and, 1163-1169

- in IgM nephropathy, 343-350
- in lipoprotein glomerulopathy, lipid-lowering therapy for, 244-249
- Nephrotoxicity
  - bisphosphonate, mechanisms of, E18
  - from fish gallbladder ingestion, 220-224
- NephTrak, URR and hematocrit values compared with different data systems, 433-441
- Newborns, continuous renal replacement therapy for, 984-989
- Niceritol, in lipid-lowering therapy for lipoprotein glomerulopathy, 244-249
- Nocturnal hemodialysis, daytime sleepiness in CRF and, 403-410
- Nodular glomerulosclerosis, case study, 508-517
- Nondiabetic kidney disease, prevalence among Zuni Indians, 1195-1204
- Nonmelanoma skin cancer, prediction after renal transplantation, 676-683
- Nonmuscle myosin IIA abnormality, in Fechtner syndrome, 95-104
- North American Indians, prevalence of hematuria with/without diabetes, 1195-1204
- NPHS2 (gene for steroid resistant nephrotic syndrome 2), in focal segmental glomerulosclerosis, 1170-1178
- Nuclear factor- $\kappa$ B, progression of chronic kidney disease, S1:3-7
- Nucleic acid amplification, determination of HBV viral load in dialysis patients, 1278-1285
- Nutrition
  - daily hemodialysis and, S1:112-115
  - depression with malnutrition in chronic hemodialysis patients and, 1037-1042
  - dietary AGEs, effect on rat remnant kidney model, S1:48-51
  - malnutrition and depression in chronic hemodialysis patients, 1037-1042
  - nocturnal hemodialysis and, S1:112-115
  - obesity effect on dialysis survival, 925-932
  - oral nutritional supplementation for peritoneal dialysis, 658-663
  - protein intake for dialysis patients, S1:133-136
- Nutritional status
  - balancing dialysis dose and protein intake for dialysis patients, S1:133-136
  - body fat mass in hemodialysis, S1:137-141
  - low-protein intake for rejection control in kidney transplant recipients, S1:146-152
  - in short bowel syndrome, conjugated bile acid replacement therapy and, 230-237
- Obesity
  - central fat distribution relationship to renal function impairment, 733-741
  - chronic renal transplant dysfunction risk and, 859-867
  - dialysis survival and, 925-932
  - renal transplantation and, 480-487
- Obstructive jaundice, hypouricemia in inpatient hospital-based facility, 1225-1232
- O-glycans, in immunoglobulin A nephropathy, 558-564
- OPD-9195, progression of nephropathy and, S1:68-71
- Open-heart surgery, acute renal failure after, 724-751
- Oral absorbent
  - effect on tryptophan metabolism in uremia, S1:38-41
  - with low-protein diet, effect on creatinine slope in CRF, S1:35-37
- Organic anion transporter in uremia, AST-120 effects on, S1:8-14
- Organ transplant recipients, quantitative tissue EBV polymerase chain reaction in, 212-219
- Orlistat, interaction with cyclosporine in renal transplant patient, 493-496
- Osmolality of urine, progression of renal disease and, 962-971
- Osteocalcin, in diagnosis of renal osteodystrophy in predialysis ESRD patients, 997-1007
- Osteoporosis
  - risk in children with idiopathic nephrotic syndrome, 1163-1169
  - steroid-sensitive nephrotic syndrome in adults and, 550-557
- Outcome
  - adenovirus infection of renal allograft, 696-701
  - in ANCA-associated glomerulonephritis, 532-538
  - Churg-Strauss angiitis, 5-year retrospective study, 776-784
  - improvement, in chronic kidney disease, 903-924
  - peritoneal clearance vs. residual renal function and, 1293-1302
  - prediction, in pauci-immune necrotizing glomerulonephritis, 29-37
- Overhydration, in hemodialysis, brain natriuretic peptide and, 1257-1266
- Overweight
  - central fat distribution relationship to renal function impairment, 733-741
  - chronic proteinuric nephropathy patients, weight loss benefits for, 319-327
  - renal transplantation and, 480-487
  - survival on dialysis and, 925-932
  - type II diabetic on PD, drug interaction in renal transplant patient, 493-496
- 22-Oxa-1,25-dihydroxyvitamin D<sub>3</sub>, for chronic hemodialysis, S1:108-111
- Oxalate excretion, in short bowel syndrome, conjugated bile acid replacement therapy and, 230-237
- Pamidronate, short-term high-dose-induced acute tubular necrosis, E18
- Pancreas transplantation, survival, for type I diabetes with renal failure, 464-470
- Pancreaticoduodenocystostomy leak, after pancreas transplant, culture-negative peritonitis and, E19
- Parathyroid hormone (PTH)
  - calcium-phosphate imbalance in cardiac valvular disease and, 411-421
  - cystosolic calcium in hepatocytes in CRF and, S1:127-132
  - in diagnosis of renal osteodystrophy in predialysis ESRD patients, 997-1007
  - in secondary hyperparathyroidism, calcimimetics in, S1:104-107



- Patient attitudes, about living donor transplants and living donor nephrectomy, 849-858
- Pauci-immune crescentic glomerulonephritis, in antiphospholipid syndrome, 1205-1211
- Pauci-immune necrotizing glomerulonephritis, clinicopathologic predictors, 29-37
- Pediatric patients. *See* Children
- Pedigrees, for familial focal segmental glomerulosclerosis, 1170-1178
- Perchloroethylene ingestion, acute renal failure requiring hemodialysis, E11
- Periodic limb movements, daytime sleepiness in CRF and, 403-410
- Peripheral arterial calcifications, prevalence/progression in ESRD, 140-148
- Peripheral arterial disease (PAD), lower-extremity, nocturnal hemodialysis for, 225-229
- Peripheral blood mononuclear cells, intracellular magnesium, QT dispersion in hemodialysis and, 196-202
- Peripheral vascular disease (PVD), amputation risk for hemodialysis patients, 162-170
- Peritoneal clearance, vs. residual renal function for patient survival and quality of life, 1293-1302
- Peritoneal dialysis (PD)
- adequacy. *See* Adequacy, peritoneal dialysis
  - albumin levels, in predicting peritonitis, 664-669
  - atherosclerotic cardiovascular disease, dyslipidemia and, S3:24
  - continuous ambulatory. *See* Continuous ambulatory peritoneal dialysis
  - culture-negative peritonitis, pancreaticoduodenocystotomy leak of pancreas transplant and, E19
  - effect on HIV-associated nephropathy ESRD survival, 1060-1064
  - for ESRD, chronic inflammation in, coronary artery calcification and, 203-211
  - inadequate, prescription changes for, 840-848
  - mortality, sedentary behavior and, 447-454
  - oral nutritional supplementation for, 658-663
  - peritonitis aminoglycoside therapy, residual renal function unaltered by, 670-675
  - predialysis care, retrospective chart review of, 49-61
  - pre-ESRD referral timing and, 310-318
  - prescription change, for inadequacy, 840-848
  - survival
    - obesity and, 925-932
    - peritoneal clearance vs. residual renal function and, 1293-1302
    - for type II diabetes mellitus, drug interaction in renal transplant patient, 493-496
- Peritoneal dysfunction, in CAPD patients, growth factors and AGEs in, S1:61-67
- Peritonitis
- aminoglycoside therapy, residual renal function unaltered by, 670-675
  - culture-negative, pancreaticoduodenocystotomy leak of pancreas transplant and, E19
  - prediction, hypoalbuminemia in peritoneal dialysis patients and, 664-669
- p16 expression, in aging kidney and chronic allograft nephropathy, 1303-1313
- p27 expression, in aging kidney and chronic allograft nephropathy, 1303-1313
- Pharmacokinetics, drug interaction in renal transplant patient, 493-496
- Pheochromocytomas, with von Hippel-Lindau gene mutations, E3
- Phosphate
- in cardiac valvular disease in hemodialysis patients, 411-421
  - wasting, in drug-induced Fanconi syndrome, 292-309
- Phosphorus
- daily hemodialysis and, S1:112-115
  - metabolic alterations, promotion of cardiovascular disease in CKD, S5:11-17
  - restless legs syndrome in uremic hemodialysis patients and, 833-839
  - in secondary hyperparathyroidism, calcimimetics in, S1:104-107
  - serum, amputation risk for hemodialysis patients, 162-170
  - uremic vascular calcifications in ESRD, S1:96-99
- Phosphorus binders, non-calcium-containing, for secondary hyperparathyroidism, S1:100-103
- Physical Component Summary, prediction of morbidity/mortality in dialysis patients, 1286-1292
- Physical function, monitoring in dialysis patients, SF-36 for, 1286-1292
- Physicians
- primary care, in improving outcome for chronic kidney disease, 903-924
  - referral patterns, for predialysis patients, 49-61
- Plasma exchange, post-renal transplant thrombotic microangiopathy and, 471-479
- Plasma protein binding, effect of tryptophan metabolism in uremia, S1:38-41
- Platelet endothelial cell adhesion molecule-1 (PECAM-1), in idiopathic membranous nephropathy, 360-365
- Pneumocystis carinii* pneumonia, in non-HIV hemodialyzed patient, atovaquone for, E13
- Podocin
- in focal segmental glomerulosclerosis, 1170-1178
  - gene mutations, post-transplant FSGS recurrence, 1314-1321
  - in pathophysiology of Alport-like syndrome, 95-104
- Podocytes
- foamy, in renal lipidoses, 891-896
  - hypertrophy, FSGS development in nephronopenia, 1179-1188
- Polyangiitis, outcome, 5-year retrospective study, 776-784
- Polycystic kidney disease (PKD)
- autosomal dominant. *See* Autosomal dominant polycystic kidney disease
  - D298 *ENOS* polymorphism in, 90-94
  - high urine volume and low urine osmolality as risk factors in, 962-971
  - type 1, D298 *ENOS* polymorphism in, 90-94
- Polymerase chain reaction (PCR)
- determination of HBV viral load in dialysis patients, 1278-1285
  - tissue EBV, for pediatric solid organ recipients, 212-219
- Polyuria, in drug-induced Fanconi syndrome, 292-309



- Population-based studies  
  of health-related quality of life in ESRD, 596-604  
  prevalence of hematuria among Zuni Indians with/without diabetes, 1195-1204
- Positron emission tomography, 18-FDG, diagnosis of renal and hepatic cysts in ADPKD, E22
- Postmenopausal women  
  dialysis-dependent, early onset menopause and use in, 643-650  
  on hemodialysis, estrogen levels in, 1240-1246
- Posttransplant recurrence of renal disease, podocin gene mutations and, 1314-1321
- Potassium-rich cardioplegia, hemodialysis during cardiopulmonary bypass and, 1247-1256
- Predialysis Survey on Anemia Management (PRESAM), demographics and patient referral data, 49-61
- Prediction  
  of allograft acceptance/function, EC survival programs and, 1140-1154  
  of ARF after cardiac surgery, 76-83  
  of nonmelanoma skin cancer after renal transplantation, 676-683  
  of outcome, in pauci-immune necrotizing glomerulonephritis, 29-37
- Prednisolone  
  long-course regimens for children with nephrotic syndrome, 1155-1162  
  low-dose, for IgA nephropathy, 972-983
- Prevalence  
  chronic kidney disease, 1-12  
  of depression in for new dialysis patients, 105-110
- Prevention  
  chronic kidney disease, early referral and, 505-507  
  exercise counseling by nephrologists, 171-178  
  K/DOQI Outcome Quality Initiative Guidelines and, S5:3-10
- Probucol, for lipoprotein glomerulopathy, 244-249
- Prognosis  
  IgM nephropathy, 343-350  
  intima-media thickness of carotid artery in ESRD, S1:76-79  
  membranous nephropathy, focal segmental glomerulosclerosis and, 38-48
- Progression  
  atherosclerotic cardiovascular disease, dyslipidemia and, S3:26  
  atorvastatin effects on, 565-570  
  chemokines and chemokine receptors in, S1:15-18  
  of chronic kidney disease, 903-924, S1:3-7  
  of chronic renal failure  
    effect of keto acids, erythropoietin and low-protein diet on, S1:26-30  
    low-protein diet with oral carbon adsorbent and, S1:35-37  
  of diabetic nephropathy, 943-949, S1:19-21  
  high urine volume, low urine osmolality and, 962-971  
  of immunoglobulin A nephropathy, low-dose prednisolone and, 972-983
- Prospective study, post-renal transplant prediction of non-melanoma skin cancer, 676-683
- Protein-creatinine ratio  
  low-dose prednisolone for IgA nephropathy and, 972-983  
  vs. protein-osmolality ratio for estimating proteinuria, 760-766
- Protein-energy malnutrition, at time of renal transplantation, 480-487
- Protein intake  
  carnitine supplementation in hemodialysis, S1:116-122  
  for dialysis patients, balancing dialysis dose and nutritional status, S1:133-136  
  low. *See* Low-protein diet  
  microalbuminuria in healthy adults and, 580-587  
  oral nutritional supplementation for peritoneal dialysis, 658-663
- Protein kinase C, progression of diabetic nephropathy, S1:19-21
- Protein kinase C inhibitor, progression of diabetic nephropathy, S1:19-21
- Protein metabolism, in liver of chronic renal failure patient, S1:127-132
- Protein-osmolality ratio, vs. protein-creatinine ratio for estimating proteinuria, 760-766
- Proteinuria. *See also* Albuminuria  
  in antiphospholipid syndrome, 1205-1211  
  asymptomatic, in mitochondriopathy, 259-264  
  chronic renal transplant dysfunction risk and, 859-867  
  diabetic nephropathy progression and, 13-21  
  in drug-induced Fanconi syndrome, 292-309  
  estimating in children, 760-766  
  in IgA nephropathy, therapeutic options for, 1129-1139  
  in IgM nephropathy, 343-350  
  and kidney disease progression, atorvastatin effects on, 565-570  
  weight loss benefits for overweight chronic proteinuric nephropathy patients, 319-327
- Protocol biopsies, of stable renal allografts, 1065-1073
- Proximal tubular damage, in patients admitted to inpatient hospital-based facility, 1225-1232
- PTH. *See* Parathyroid hormone
- Pure red blood cell aplasia, after erythropoietin, cyclosporine for, 692-695
- QT dispersion in hemodialysis, intracellular magnesium and, 196-202
- Quality of care  
  for anemia, effect of hemoglobin variability on, 111-124  
  for diabetic hemodialysis patients, 125-131
- Quality of life  
  in ESRD, socioeconomic status and, 186-195  
  health-related  
    in ESRD, population-based study of, 596-604  
    in hemodialysis patients of different ethnicities, 605-615  
  peritoneal clearance vs. residual renal function and, 1293-1302
- Quantitative polymerase chain reaction, for pediatric solid organ recipients, 212-219
- Questionnaire, on negative attitudes for self-care dialysis in ESRD, 380-385
- Race  
  acute renal failure after open-heart surgery, 724-751

- health-related quality of life for ESRD hemolysis patients, 605-615
- Radical nephrectomy, hand-assisted laparoscopic, rhabdomyolysis after, E5
- Radioimmunoassay (RIA), albuminuria in diabetes mellitus, 336-342
- RAGE (receptor for advanced glycation end products), peritoneal dysfunction in CAPD patients and, S1:61-67
- Ranitidine, Fanconi syndrome induction and, 292-309
- Rat kidney  
diabetic, OPB-9195 amelioration of glomerular lesions in, S1:68-71  
effects of dietary AGEs on, S1:48-51  
uremic, effects of oral absorbent on gene expression profile in, S1:8-14
- Reactive oxygen species, homocysteine in uremia, S1:123-126
- Receptor for advanced glycation end products (RAGE), peritoneal dysfunction in CAPD patients and, S1:61-67
- Reciprocal creatinine slope, in CRF, effects of low-protein diet with oral carbon adsorbent on, S1:35-37
- Recombinant human erythropoietin (rHuEPO)  
erythrocyte expression of complement proteins and, 179-185  
hypo-responsive patients  
CD34+ cells in, 624-636  
levocarnitine for, S4:27-34  
with keto acids and low-protein diet for CRF, S1:26-30  
pure red blood cell aplasia after, cyclosporine for, 692-695
- Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL), S1:22-25
- Referral  
early, in chronic kidney disease, 505-507  
improving outcome in CKD, 903-924  
timing, pre-ESRD and, 310-318
- Relapse rate, long-course prednisolone regimens for children with nephrotic syndrome, 1155-1162
- Reliability, of URR and hematocrit values, data comparisons, 433-441
- Remnant lipoprotein particles, as target for lipid-lowering therapy in dialysis patients, S1:72-75
- Renal angiomyolipoma, pulmonary lymphangiomyomatosis and, 877-883
- Renal arterial thrombosis, delayed angioplasty after, E20
- Renal artery stenosis  
and blood pressure and renal function in elderly, 990-996  
in diabetic nephropathy with uncontrolled hypertension, 351-359
- Renal biopsy  
of acute renal failure after fish gallbladder ingestion, 220-224  
allograft dysfunction, drug-induced AIN in, 1116-1121  
antiphospholipid syndrome, 1205-1211  
EBV load determination for, 212-219  
of familial focal segmental glomerulosclerosis, 1170-1178  
granulomatous interstitial nephritis, 714-719  
IgM nephropathy, 343-350  
light-and-heavy-chain deposition disease, 508-517  
mitochondriopathy, 259-264  
nephrotic syndrome with acute renal failure in diabetes mellitus, 1327-1333  
outcome prediction in pauci-immune necrotizing glomerulonephritis, 29-37
- Renal cysts, in ADPKD, diagnosis by 18-FDG-PET, E22
- Renal failure. *See* Acute renal failure; Chronic renal failure; End-stage renal disease
- Renal functional reserve, in stable allografts, 1065-1073
- Renal function impairment, central fat distribution and, 733-741
- Renal insufficiency, health-related quality of life in, 596-604
- The Renal Network Data System, URR and hematocrit values compared with different data systems, 433-441
- Renal osteodystrophy  
diagnostic markers in predialysis ESRD patients, 997-1007  
in uremic patients on maintenance hemodialysis, TRACP and, 1052-1059
- Renal parenchymal malacoplakia, causing acute renal failure, E21
- Renal replacement therapy. *See also* Hemodialysis; Peritoneal dialysis; *specific types of renal replacement therapies*  
negative attitudes for self-care dialysis in ESRD, 380-385  
selection, for ESRD with HIV infection, 279-291
- Renal transplantation  
cadaveric, pseudoaneurysm of iliac artery and, 488-492  
for children with lupus nephritis, 455-463  
chronic allograft nephropathy in aging kidney, cyclin-dependent kinase inhibitor genes and, 1303-1313  
de novo thrombotic microangiopathy and, 471-479  
endothelial cell survival programs, significance of, 1140-1154  
living donors, living, patient attitudes on, 849-858  
overweight and obesity in, 480-487
- Renal transplant recipients  
atherosclerotic cardiovascular disease, dyslipidemia and, S3:24-25  
hypercholesterolemic, HMG-CoA reductase inhibitors for, 1088-1096  
pediatric, acute myelo-monocytic infiltrate in lower esophagus, E16  
pediatric, vascular function in, 684-691  
prediction of nonmelanoma skin cancer in, 676-683  
rejection control, low-protein intake for, S1:146-152  
renal tubular acidosis with repeated rejections and chronic allograft nephropathy, E6  
structural and functional correlations of stable allografts, 1065-1073  
survival, for type 1 diabetes with renal failure, 464-470
- Renal tubular acidosis, in renal transplant recipient with repeated rejections and chronic allograft nephropathy, E6
- Renal tubular dysfunction in chronic alcohol abuse, Fanconi syndrome and, 292-309
- Renal vasculitis, ANCA-associated, 5-year retrospective study of, 776-784
- Renovascular disease, and blood pressure and renal function in elderly, 990-996

- Residual renal function  
 in chronic renal failure, circulating inflammatory markers and, 1212-1218  
 compared with peritoneal clearance for patient survival and quality of life, 1293-1302  
 in peritonitis after aminoglycoside therapy, 670-675
- Restless legs syndrome, in uremic hemodialysis patients, 833-839
- Reverse-transcription polymerase chain reaction, hepatitis C virus-associated tubulointerstitial injury, 767-775
- Rhabdomyolysis, after hand-assisted laparoscopic radical nephrectomy, E5
- Risk assessment, use of comorbidity index for, 149-161
- Risk factors  
 for amputation in hemodialysis, 162-170  
 for medication-related problems in ambulatory hemodialysis, 386-393  
 obesity effect on dialysis survival, 925-932
- Salicylate intoxication, Fanconi syndrome induction and, 292-309
- Salmonella typhi*, hemolytic uremic syndrome and, 709-713
- Sedentary behavior, decreased survival in dialysis patients and, 447-454
- Self-care dialysis, for ESRD, barriers toward, 380-385
- Sensorineural hearing loss, *ATP6B1* gene mutations in autosomal recessive distal RTA and, 238-243
- Septic shock, acute renal failure, proinflammatory cytokines and, 62-75
- Shiga toxin bacteremia  
 hemolytic uremic syndrome and, 709-713  
 nondiarrheal hemolytic uremic syndrome with UTI and, E4
- Short bowel syndrome, conjugated bile acid replacement therapy for, 230-237
- Skin cancer, nonmelanoma, prediction after renal transplantation, 676-683
- Skin whitening cream, causing membranous nephropathy, 250-253
- Sleepiness, daytime  
 in chronic renal failure, 403-410  
 in stable hemodialysis patients, 394-402
- Smoking, and albuminuria in prediction of diabetic nephropathy progression, 13-21
- Social isolation, as barrier for self-care dialysis in ESRD, 380-385
- Socioeconomic status, quality of life in ESRD and, 186-195
- Sodium ferric gluconate  
 in chronic hemodialysis, safety of high dosing, 651-657  
 safety profile, S5:18-25
- Sodium wasting, in drug-induced Fanconi syndrome, 292-309
- Soluble Fas, as predictor of atherosclerosis in ESRD, 1043-1051
- Soluble tumor necrosis factor- $\alpha$  receptors, prediction of ARF in septic shock, 62-75
- Spectrophotometry, estimation of delivered dialysis dose, 1026-1036
- Statins, for treating high low-density lipoprotein, S3:41-51
- Steatorrhea, in short bowel syndrome, conjugated bile acid replacement therapy for, 230-237
- Stem cell factor, crescentic glomerulonephritis and, 785-795
- Sternotomy, mediastinal povidine-iodine irrigation iodine toxicity, 702-708
- Steroid-sensitive nephrotic syndrome, long-term complications in adults, 550-557
- Steroid therapy  
 for idiopathic nephrotic syndrome in children, metabolic bone disease risk and, 1163-1169  
 low-dose, for immunoglobulin A nephropathy, 972-983  
 for proteinuria in IgA nephropathy, 1129-1139
- Suramin, Fanconi syndrome induction and, 292-309
- Survival  
 continuous renal replacement therapy for young children and, 984-989  
 dialysis modality effect on HIV-associated nephropathy ESRD, 1060-1064  
 of dialysis patients, sedentary behavior and, 447-454  
 hemodialysis, pre-dialysis hypertension and, 814-821  
 long-term, kidney-pancreas transplant for type 1 diabetes mellitus and, 464-470  
 obesity of dialysis patients and, 925-932  
 pre-ESRD referral timing and, 310-318  
 renal transplantation for children with lupus nephritis and, 455-463  
 time of day for hemolysis and, 796-806
- Sympathetic tone, dialysis-related hypotension and, 807-813
- Tacrolimus, thrombotic microangiopathy after renal transplant and, 471-479
- Tartrate-resistant acid phosphatase, uremic patients on maintenance hemodialysis, 1052-1059
- Tetracycline, Fanconi syndrome induction and, 292-309
- T-help cell subtype balance, IgA nephropathy progression and, 371-379
- Therapeutic trial method, significance of morphologic factors for, 38-48
- Third National Health and Nutrition Examination Survey (NHANES III), prevalence of chronic kidney disease, 1-12
- Three-dimensional magnetic resonance angiography, of renal artery stenosis in diabetic nephropathy with uncontrolled hypertension, 351-359
- Thrombi, glomerular lipoprotein, lipid-lowering therapy for, 244-249
- Thrombotic microangiopathy, post-renal transplant, 471-479
- Thymidine phosphorylase, in idiopathic membranous nephropathy, 360-365
- Time of day, effect on hemodialysis survival, 796-806
- Tinzaparin, causing diffuse alopecia in HD patient, E15
- Transforming growth factor- $\beta$   
 gene polymorphisms, diabetic nephropathy and, 22-28  
 progression of chronic kidney disease, S1:3-7
- Treatment algorithm, effect of hemoglobin variability on anemia management and, 111-124
- Triglycerides, lipogenesis in uremic hyperlipidemia, S1:84-88
- Tryptophan, metabolism in uremia, effect of oral adsorbent on, S1:38-41

- Tuberous sclerosis, renal angiomyolipoma, pulmonary lymphangioleiomyomatosis and, 877-883
- Tubular defects, in drug-induced Fanconi syndrome, 292-309
- Tubular epithelial cells, cell-surface molecules, in crescentic glomerulonephritis, 950-961
- Tubular necrosis, outcome prediction in pauci-immune necrotizing glomerulonephritis, 29-37
- Tubulointerstitial injury  
chemokines and chemokine receptors in, S1:15-18  
hepatitis C-virus-associated, 767-775
- Tumor necrosis factor- $\alpha$ , 62-75  
prediction of ARF after allograft ischemic injury, 1074-1087  
progression of chronic kidney disease, S1:3-7
- Tumor necrosis factor- $\alpha$  receptors, prediction of ARF in septic shock, 62-75
- Typhoid fever, with hemolytic uremic syndrome, 709-713
- Ultrasound, of vasculature, gender differences in, 429-432
- United States population, prevalence of chronic kidney disease, 1-12
- United States Renal Data System, 2002 annual data report, S2:1-256
- Urea clearance, comparison of dual dialyzers in parallel and series, 1008-1015
- Urea filtration rate/volume, improvement after peritoneal dialysis prescription change, 840-848
- Urea reduction ratio, comparison in different data systems, 433-441
- Uremia. *See also* End-stage renal disease  
carnitine supplementation, S4:4-12  
carnitine supplementation in hemodialysis, S1:116-122  
daytime sleepiness in CRF and, 403-410  
homocysteine in, S1:123-126  
hyperlipidemia of, lipogenesis in, S1:84-88  
maintenance hemodialysis, TRACP and, 1052-1059  
with rHuEPO hyporesponsiveness, levocarnitine for, S4:27-34  
tryptophan metabolism, effect of oral adsorbent on, S1:38-41  
tumoral calcinosis, daily home hemodialysis for, E12  
vascular calcifications in ESRD, S1:96-99
- Uric acid wasting, in drug-induced Fanconi syndrome, 292-309
- Urinary tract infection, with nondiarrheal hemolytic uremic syndrome, E4
- Urinary urate wasting, in patients admitted to inpatient hospital-based facility, 1225-1232
- Urine volume, high, progression of renal disease and, 962-971
- Vaccinations, in ESRD with HIV infection, 279-291
- Vascular access  
arteriovenous fistula, vasculature in women and, 429-432  
blood flow, for fistulae surveillance, 132-139  
for ESRD with HIV infection, 279-291  
resistance, blood flow during hemodialysis and, 132-139  
surveillance, blood flow and resistance during hemodialysis, 132-139  
thrombosis risk in hemodialysis, MTHFR reductase gene polymorphism and, 637-642
- Vascular calcifications, in end-stage renal disease, S1:96-99
- Vascular endothelial growth factor, in idiopathic membranous nephropathy, 360-365
- Vasculature  
function, in pediatric renal transplant recipients, 684-691  
gender differences for venous access, 429-432
- Vasculitides, ANCA-associated, histologic and immunohistologic study of, 539-549
- Vasculitis, antiphospholipid antibody-associated, 1205-1211
- Venovenous hemofiltration, for infants, 984-989
- Vietnam, ichthyotoxic acute renal failure in, 220-224
- Vitamin C, effect on EPO response in hemodialysis, 1233-1239
- Vitamin D analogues  
with calcimimetics, for secondary hyperparathyroidism, S1:104-107  
for secondary hyperparathyroidism, S1:100-103
- V $\kappa$ l light chain, in myeloma tubulopathy, 497-504
- Waist-hip ratio, renal function impairment and, 733-741
- Wegener's granulomatosis  
ANCA antigen specificity in, 539-549  
outcome, 5-year retrospective study, 776-784  
proinflammatory IL-1 $\beta$ /il-1 $\alpha$  genotype and, 933-942
- Weight  
excessive. *See* Obesity  
loss, benefits for overweight chronic proteinuric nephropathy patients, 319-327  
steroid-sensitive nephrotic syndrome in adults and, 550-557
- Wilms' tumor suppressor gene, Alport syndrome-like basement membrane changes in Frasier syndrome, 1110-1115
- Women, vasculature of, arteriovenous fistula placement and, 429-432
- Xenical, interaction with cyclosporine in renal transplant patient, 493-496
- Zopiclone-induced acute interstitial nephritis, E17
- Zuni Kidney Project, prevalence of hematuria with/without diabetes, 1195-1204



